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Abstract 
 
Nanotechnologies are rapidly expanding because of the opportunities that the new 
materials offer in many areas such as the manufacturing industry, food production, 
processing and preservation, and in the pharmaceutical and cosmetic industry [1-3]. Size 
distribution of the nanoparticles determines their properties and is a fundamental 
parameter that needs to be monitored starting from the small scale synthesis up to the 
bulk production and in the quality control of nanotech products on the market. This concept 
holds true especially because on particle size and particle size distribution (PSD) depend 
some important characteristics of nanoparticles such as stability, toxicity and functioning 
(just to name a few). An example is the distribution of nanoparticles in different biological 
compartments with the result that the same chemical species can be toxic or not according 
to its size, while in the context of drug delivery and cosmetic industry [4], specific targets 
require well-defined size distributions (in anticancer therapy, nano particles between 70 
and 200 nm are used drug vector while micro particles can act as cell- like tumor 
vaccines). 
As a consequence of the increasing number of application the EU regulatory authorities is 
implementing the EU's groundbreaking chemicals legislation of nanomaterials. Aims are 
the benefit of human health and the environment as well as the innovation and 
competitiveness of chemical industry. Companies have to comply with the legislation, 
advance the safe use of chemicals, provide information on chemicals and address 
chemicals of concern. This introduces the obligation for companies that make use of 
nanomaterials both to compliance with such regulations and to acquire and use analytical 
platforms that allow the assessment of the size parameters of the nanomaterials they use. 
This duty is considered to be of capital importance, so that the problem of the 
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characterization of nanosized materials has recently been summarized in the slogan 'no 
data, no market'. 
Size exclusion chromatography (SEC) is nowadays the golden standard for size 
separation of dispersed samples, because of its simplicity of use, relative low number of 
parameters to be kept under control for the experiments, ease method set up, and most of 
all because its hyphenation with UV-Vis, Refractive index or fluorescence detection makes 
it possible to have an analytical platform with the appealing feature of easy and rapid 
method development and relatively easy method validation. Such features have been 
historically enough for chemical laboratories, especially in the industry, to choose SEC as 
standard technique, especially when reproducibility of analysis is of capital importance 
because the research is carried on on the cooperation of different laboratories. However 
SEC separation have some drawbacks, that become very important for niche application, 
when it might fail for two main reasons: (1) it covers a low Mw range of separation and (2) 
analysis conditions are rigid and separation method is very sensitive to parameters such 
as pH, ionic strength and type of anion and cation of the carrier solution. 
It is a matter of fact that Asymmetric Flow Field-Flow Fractionation (AF4) and Hollow Fiber 
Flow Field-Flow Fractionation (HF5) have both separation range far away broader than 
SEC and analysis conditions are much more flexible. For this reasons the scientific 
community is starting to propose AF4 and HF5, if not the promised next golden standard, 
at least a valuable and effective complementary technique to SEC. However, it is 
necessary to distinguish between the flexibility and wide applicability of FFF, from the 
costs related to this flexibility. As an example it is true that almost every carrier solution 
can be used as mobile phase since the FFF channel is simply empty and separation relies 
on physical principles rather than on chemical interactions. But on the other hand, like it 
happens in SEC, sometime there are only few buffers, pH or ionic strengths that allow for 
a proper separation. Therefore the FFF flexibility in daily use is sometime lower than a 
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theoretical speculation would suggest. However, for niche applications it is still true that 
FFF offers interesting features, which can be used to investigate complex issues. 
In my thesis, I propose Asymmetrical Flow Field-Flow Fractionation iphenated with 
Multiangle light Scattering (MALS), Differential Refractive Index (DRI) and UV-Vis 
detection as analytical platform to determine particle size distribution and gain a deep 
characterization of nanoparticles in dispersion. AF4 is a separation technique consisting in 
the size separation according to the hydrodynamic radius of the analytes, while MALS 
coupled with DRI and/or UV-Vis detection allow for the independent determination of the 
radius of gyration or root means square radius (rg or RMS) and molecular mass (Mw) of the 
analytes. 
Its uses are applied to different samples with the purpose to address some specific issues. 
In particular Section 2 is focused on the field of liposomal technologies: it aims to discuss 
in depth that several technique are today used for the size and morphological 
characterization of lipidic vesicles (Chapter 3), but despite liposomal technologies were 
introduced decades ago, still today the analytical challenges they put on the table suffer 
the lack of a size based separation and characterization technique, applicable in a wide 
series of dispersing medium, and able to provide deep insight both on morphological or 
structural aspects and into functional aspect of liposomes. Chapter 4 is devoted to the 
investigation of the particle size distribution and aggregates formation of liposomes 
dispersed in different medium, while in Chapter 5 the functional features of a liposomal 
drug vector in terms of its biological and physical interaction with blood serum components 
is put into the spotlight. A deep and comprehensive approach to understand the behavior 
of lipid vesicles in terms of drug release and fusion/interaction with other biological affine 
species is described, together with weaknesses and strength of the developed method. 
Section 3 contains two chapters both devoted to the rapid screening and fast dimensional 
characterization of functional nanoparticles. Chapter 6 is focused in particular on the size 
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characterization and size stability of a new generation of metastable drug vectors: the 
Metal Organic Frameworks. The conjugation of the vector with various azidothymidine 
analogues in evaluated, together with size and size stability of particles. Chapter 7 shows 
that it is possible to successfully use HF5-ICP-MS for the rapid screening of the presence 
of nanoparticles in samples of tattoo inks. This chapter, rather than describe a deep and 
comprehensive characterization, aims to show that with few steps it is possible to gain 
qualitative information on the content of metallic particulate in the sample. 
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Section 1: The Flow Field-Flow 
Fractionation Technique  
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1.1 – Introduction on FFF: nature, mechanism and 
operational modes 
Field-flow fractionation (FFF) is a family of flexible elution techniques capable of 
simultaneous separation and measurement.  Its sample domain extends across a broad 
macromolecular-colloidal-particulate continuum from about 1 nanometer to more than 100 
micrometers [5]. 
These techniques are based on the action of two fields: separation is achieved through a 
laminar flow of mobile phase and a perpendicular force-field, as illustrate in Figure 1. 
 
Figure 1: FFF works in the basis of the action of two perpendicular fileds. 
 
FFF sub-techniques are distinguished and classified according to the great number and 
type of applicable force-field: FFF is therefore extraordinarily versatile. 
The most common sub-techniques and the corresponding force-field are listed in Table 1. 
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Field type Technique 
Cross-flow (Fl) Flow FFF (FlFFF) 
Hollow – fiber (FlFFF) 
Sedimentation  (Sd) Sedimentation FFF (SdFFF) 
Centrifugal (SdFFF) 
Gravitational FFF (GrFFF) 
Thermal (Th) Thermal FFF (ThFFF) 
Electrical (El) Electrical FFF (ElFFF) 
Magnetic (Mg) Magnetic FFF (MgFFF) 
Dielectric (Dl) Dielectric FFF (DlFFF) 
Table 1: applicable Force-field and corresponding FFF techniques. 
  
An FFF system is composed by an empty channel with at least one capillary dimesion: this 
makes FFF a soft fractionation technique, highly biocompatible and suitable for samples of 
biological interest [6, 7].	  
Once injected in the separation channel, analytes take position across a laminar flow, 
whose profile is parabolic, with maximum velocity in the channel center and minimum 
close to channel wall. This position determines many important parameters, such as 
selectivity, efficiency and others. Most of all the elution order and the two possible 
operational mode in FFF, namely normal mode and Steric-Hyperlayer, are determined: 
 
(1) Normal mode: analytes are pushed by the field toward the lower potential wall, the 
accumulation wall, and their local concentration increases with decreasing distance from 
the wall itself. A concentration gradient is then created, and it promotes a diffusive 
transport which opposes the transport generated by the external force-field. When both are 
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balanced, the sample reaches a position of dynamic equilibrium with a determined 
distance from the accumulation wall. According to this distance analytes penetrates the 
parabolic flow profile and exerience different flow velocity and separation occurs. 
 
(2) Steric-Hyperlayer mode: for micrometric particles, the diffusive transport opposing the 
force-filed is negligible. Therefore particles originate a layer whose tickness depends on 
the size of the particles themselves. Larger particles forme thicker layers and penetrates 
into regions of the parabolic flow profile of higher speeds, and are eluted faster. During 
elution, the movement of particles towards the accumulation wall is balanced by the so-
called lift-forces, which are induced by the mobile phase flow. Therefore the larger the 
particles the earlier they elute. 
1.2 – Flow Field-Flow Fractionation 
Flow Field-Flow fractionation (FlFFF) is in absolute the most diffuse and versatile FFF 
technique. The separation is obtained as a combination of a parabolic flow and 
perpendicular flow (cross-flow) of carrier solution, the latter constitutes the external force-
field. Asymmetric Flow Field-Flow Fractionation (AF4) and Hollow Fiber Flow Field-Flow 
Fractionation are the FlFFF technique who experienced the main success and 
development, they are in fact the widest used among commercially available FFF 
techniques. 
Separation results from the application of a flow stream of carrier within a capillary channel 
together with a perpendicular, hydrodynamic flow. Since the separations depends only 
upon the carrier flows applied, because of the lack of a packed stationary phase and since 
no chemical interactions or shear stress/degradation mechanism are involved, AF4 has a 
unique gentle separation mechanism: issues like shear forces or particle alteration are 
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therefore avoided. Furthermore analyses are feasible in a wide series of dispersing 
medium. 
The separation device is a flat channel with a trapezoidal shape and capillary height, as 
shown in Figure 2. 
 
Figure 2: AF4 channel 
 
For the sample analysis, particles are at first introduced in the channel and a focussing 
step takes place by applying two opposing streams of carrier, allowing the sample to 
concentrate on a narrow band. When the elution starts, a stream of carrier drives particles 
toward the channel, while the perpendicular hydrodynamic field is applied, as indicated by 
dark blue arrows and light blue arrows in Figure 2. This causes the particles to be driven 
toward the accumulation wall (the inferior surface of the channel), and their concentration 
to builds up against the wall. A concentration gradient is therefore created, and causes the 
particles to diffuse away from the wall because of an opposing, diffusive flux. Different 
particles form layers of different thicknesses, and the greater the thickness the higher the 
elevation at which the cloud of particle travel along the channel because and penetrates 
into a faster streamline of the parabolic flow profile. Therefore, in AF4 retention times of 
particles are inversely proportional to their diffusion coefficient (D), and directly 
proportional to the hydrodynamic diameter [8]. A pump generates the two perpendicular 
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flows by splitting the longitudinal flow, into a second one (the cross-flow) across the 
accumulation wall (the only permeable wall of the channel).  
1.3 – Asymmetric Flow Field-Flow Fractionation (AF4) 
In normal mode AF4, analytes concentration as a function of the distance from the 
accumulation wall, c(x), depends upon the forces generated by the cross-flow stream (first 
term of equation 1) and the opposite, duffusive flux (second term of equation 1): 
 
 (1) 
 
From equation 1 the expression for c(x) can be obtained: 
 
 (2) 
 
Where c0 is the analyte concentration at x=0, that is close o the accumulation wall, as 
indicated in Figure 2. 
The ratio !/!(!)   is expressed as !, it represents the mean distance from the accumulation 
wall and. The retention parameter  depends upon !:  
 
 (3) 
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 (4) 
The retention parameter can be obtained from experimentally, it is in fact the ratio between 
t0  (void time) and tr  (retention time): 
 
 (5) 
 
Both t0 and tr can readly be calculated, according to the following two equations: 
 
 (6) 
 
 
 (7) 
  
where V0 is the void volume, Vc and Vout  are the velocities of longitudinal and cross-flow, 
respectively. Equation 7 is of capital importance since it highlights the proportionality 
between retention time and diffusivity of particles, since both tr and D appear. On the other 
hand, the Stokes-Einstein equation relates the diffusion coefficient D to the hydrodynamic 
diameter d of particles:  
 (8) 
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For this reason in AF4 it is usually reported that the retention time is inversely proportional 
to the diffusion coefficient and proportional to the hydrodynamic radius of particles: 
tr !
1
D  
tr ! dh   
 
The following equation explicits the raltionship between tr and the hydrodynamic diameter 
of the eluted species, that can be directly calculated from the experimental retention time 
value: 
r
c
h ttwV
kTVr
0
2
02
πη
=  (9) 
1.4 – Hollow Fiber Flow Field-Flow Fractionation 
Historically AF4 has been the first FlFFF technique commercially available. However in the 
recent years another technique has gained increasing interest: the Hollow Fiber Flow-Field 
Flow Fractionation (HF5). 
HF5 is based on the same principles of AF4 for the size-based separation of colloids so 
that the same sequence steps is shared in both techniques: sample injection, sample 
focusing and relaxation, sample elution with an external field generated by a stream of 
carrier solution. Also sample separation modes are the same and governed from the same 
principles: diffusive flux in normal mode, and steric volume of particles together with lift 
forces in steric hyperlayer mode. The main difference is due to the geometry of the 
separation device: in HF5 it is a cylindrical, empty channel, rather than a trapezoidal , flat 
one.  
The retention ratio is expressed according to the following equation:  
fr Ur
D
t
tR 40 ≅=  (10) 
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Because channel volume in HF5 is tens of time lower compared to that of AF4, it allows for 
channel miniaturization. This is a key feature because some key advantages were 
achieved with HF5: lower sample dilution that leads to lower detection limit and higher 
sensitivities, lower mobile phase consumption. Also detector flow is lower, a feature which 
makes HF5 the elective FlFFF technique for the on-line coupling with MS. Furthermore 
channels are more easy to handle and disposable: for application in biochemistry 
problems like run to run carry over and sterility are with HF5 fixed. 
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Chapter 2 – Detection in FFF 
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2.1 - Introduction  
Once analytes are separated a detector is required to determine when the sample is 
eluted. Detection in FFF can be performed both off-line and on-line. In the first case the 
eluate is collected for subsequent analyses. When performed on-line, one or multiple 
detectors are placed after the separation system, virtually with no limitation on the number. 
The most common detectors are UV-Vis, Refractive Index (RI), fluorescence (FL) and 
Multi Angle Light Scattering (MALS) detectors; furthermore, increasing application of FFF 
on-line coupled with MS, especially ICP-MS are now available on the literature. Some 
limitations are still to be overcome for the coupling with other ionization source; up to now 
the main problems are (1) the high salt concentration required for separation which 
suppress ionization; and (2) the high detector flow that introduces technical issue to be 
fixed for the correct working of the FFF-MS systems. 
2.2 -  UV/Vis Spectrophotometry 
UV-Vis detection is widely used for the characterization of colloids. It is relatively cheap, 
quite easy to handle and the on-line coupling with FFF apparatus easy. It allows for the 
characterization of the spectroscopic features of samples, and this is very interesting 
because often colloids have size dependent properties, that can be investigated. 
The major drawback of UV-Vis detection is that it is a concentration detector, and for an 
optimal use signal should be proportional only to the concentration of analytes. However, 
when the sample is a colloid, the bigger the particles the more signal is generated because 
of scattering of  photons rather than to absorption. As a consequence, sample 
quantification is not straightforward because the UV signal is actually a turbidimetric 
measure. The sensitivity varies according to particles size, with consequent 
underestimation of the population of bigger particles. The more particle size approaches 
detection wavelength the more this phenomenon affects the measurement. 
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2.3 – Differential  Refractive index (DRI) detection 
DRI detectors experienced a great success in colloid characterization because they are 
the best choice for dissolved polymers, especially when separated with SEC columns. 
When analysing narrowly dispersed samples, DRI signal can be converted directly to a 
concentration profile, but with increasing sample polidispersity this holds not always true: 
signal response is proportional not only to particle concentration but also to particle size. 
For these reasons RI detection experiences the same limitation of UV-Vis detection. 
Furthermore DRI detectors require the pressure of the separation system quite stable. It is 
the case of SEC whose methods are nothing more than a single step of isocratic flow and 
isocratic mobile fase. On the contrary, AF4 methods often require flow gradients to 
separate particles in a reasonable time, causing pressure drifts or progressive pressure 
drops in the DRI cell, making this detection technique hardly applicable. 
2.4 – Light Scattering 
Light scattering (LS) methods are broadly used for the size analysis of colloids. LS is a 
non-destructive technique, it is widely used both in batch mode and on-line coupled with 
separation techniques, such as SEC and FFF. This configuration allows at first to size 
separate particles and then to analyse a series of ideally mono-dispersed slices of sample, 
so that the information content is higher than in the case of a batch mode analysis whose 
result in terms of particle size would be just a mean. 
Dynamic light scattering (DLS) is often coupled with FFF, it measures the diffusivity of 
samples by processing the interference profile decays generated by particles in brownian 
motion. Diffusivity is then turned into the hydrodynamic radius of particles through the 
Stokes-Einstein equation. DLS is easy to couple with FFF systems, however its use is 
sometime limited. It is a matter of fact that for a good DLS experiment, measurement time 
should be at least some tens the time that interference profiles takes to completely decay.  
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As a consequence detector flow in FFF has to be tuned according to the DLS need to 
detect particle for a sufficient time, which is a severe complication during FFF method 
development and experiments. Bigger particles take more time to decay, so that for 
example it is easy to correctly characterize few nanometres proteins, but hard to 
characterize tens or hundreds nanometres radius nanoparticles. Such a procedure is 
particularly time consuming when nothing but decrease elution flow can be done.   
Multiangle light scattering was first coupled with FFF during the 90s [9]. The theory on size 
and mass calculation based on static light scattering has been extensively explained. 
Briefly, when refractive index increment (dn/dc) and sample concentration are known, 
MALS can provide Mw while, independently from concentration or other sample 
specification and without assumption on particle conformation or shape, it provides the 
root mean square (RMS) radius, which represents the mass-averaged distance of each 
mass element of the NP from its centre of gravity. 
MALS detection does not require any calibration step, in this sense it is an absolute 
method: particle size and Mw are computed by using the physical phenomenon of 
scattering that occurs when a colloidal sample is illuminated by photons. A MALS detector 
has multiple diodes arranged around the sample cell so that the angular intensity of 
scattered light is measured as a function of angle. The Zimm formalism [10] relates these 
quantities trough the following equation: 
  
K *c
R !,c( )
=
1
MwP !( )
+ 2A2c  (11) 
where R(θ,c) is the excess Rayleigh ratio of the solution and depends from the scattering 
angle θ and concentration c; Mw is the weight-averaged solute molar mass; A2 is the 
second virial coefficient in the virial expansion of the osmotic pressure, while K* is a 
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constant. P(θ) describes the angular dependence of the scattered light, and is related to 
the rms radius. The expansion of P(θ) to first order gives: 
 (12) 
where rg is the RMS radius.  
If a sample is very diluted and its concentration tends to zero (c→0), the second term of 
eq. 10 can be neglected, and the quantity directly measured from every diode in the MALS 
cell, R(θ) is directly proportional to Mw: 
 (13) 
Combination of eq. 12 with eq. 13 results in eq. 14, which shows that by plotting !(!,!)!∗!  as a 
function of !"#! ! 2 , the result is a series of point that upon linear regression give a curve 
with slope equal to rg and intercept equal to Mw:  
 (14) 
If both Mw and RMS radius distributions are known, particle shape and density information 
are accessible (deriving from the Mw to RMS ratio). MALS detection is applicable in the 
range 10 nm – 1 µm, and since scattering intensity increases with particle size, the bigger 
the former the higher the sensitivity. 
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Chapter 3 – Liposome 
characterization 
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3.1 – Liposomes 
Liposomes and phospholipid vesicles are composed of one or multiple double layers of 
lipids or phospholipods that surround an aqueous core [11]. They form spontaneously 
upon mechanical agitation of an aqueous solvent and lipids. The size of liposomes may 
vary from tens of nanometers to tens of micrometers, and they can be unilamellar or 
multilamellar according to the number of lipid bilayers. It is a common practice to classify 
liposomes as a function of these characteristics, the three main classes are: 
- SUVs (Small Unilamellar Vesicles), for particle size smaller than 100 nm; 
- LUV (Large Unilamellar Vesicles), for particle size in the range 100 - 800 nm, 
- MLVs (Multilamellar Vesicles), for micrometer sized particles. 
Several techniques are nowadays available for liposome synthesis. MLV dispersions can 
be obtained by rehydration of a lipid film, sonication of this dispersion leads to the 
formation of SUVs [12], which may also be obtained by extrusion through filters of suitable 
porosity [13, 14], or by high pressure homogenisation [15]. LUV can be prepared using  
techniques suche as detergent removal from a dispersion of micelles [16] or by reverse 
phase evaporation [17]. 
Liposomes are interesting for their ability to incorporate both hydrophilic compounds (in the 
aqueous core), as well as lipophilic or amphiphilic compounds (in the lipid membrane) [18]. 
As drug vector devices liposomes have high versatility, thanks to their structure, to their 
biocompatibility, to the wide choice of phospholipid compositions, and last but not least 
thanks to the use of additives such as cholesterol or species able to target their fate, like 
antibody or proteins [19, 20]. A number of liposomal formulations are undergoing clinical 
trials for FDA approval, or have already been approved (AmBisome ® - Amphothericin B; 
Doxil ® / Caelyx ® - doxorubicin; and DaunoXome ® - daunorubicin, to report some 
examples). 
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3.2 – Morphological and functional characterization of 
liposomes 
Monitor the size and size distribution of liposomes is crucial because of several aspects. 
First of all, during manufacturing processes PSD provides important information on 
preparation techniques and for process optimization, from the small-scale synthesis to the 
industrial scale-up. 
Furthermore, particle size affects physical stability of liposomes, since phenomenon like 
fusion of vesicles of small size or aggregation of MLVs are common. 
Most of all, PSD is important on the context of the applications in medicine and drug 
delivery. Size and structure tune the ability to incorporate or encapsulate pharmaceutical 
compounds: while for lipophilic and amphiphilic compounds high ratios between 
membrane thickness and core volumes is required, the opposite is for hydrophilic drugs, 
as shown in Figure 3. 
  
Figure 3: Liposome incorporating lipophilic drug in the lipid bilayer and hydrophilic drug in the aqueous 
core 
 
Vectorization of chemotherapeutic agents is one of the main application of liposomes as 
drug carriers, because of the great number of advantages of this formulation:  
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(1) protection of chemotherapeutic agents from metabolism and degradation during 
circulation in the blood stream; 
(2) administration of poorly soluble agents; 
(3) administration of high doses limiting toxic effects; 
(4) high local concentration of the drugs in the  target site.  
Both particle size and PSD determine the fate of liposomes: parenchymal cells of the liver 
absorb small size vesicles with radius up to 70 nm, while liposomes larger than 300 nm 
accumulate in the spleen. PSD affects bio-distribution [21], as an example cancerous 
tissues have a very high permeability according to particle size: a cut-off of 400 - 600 nm 
was determined for liposomes which penetrate through the tumour cells.  
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3.3 – Common techniques for liposome characterization 
Despite a wide choice of techniques is available for liposome characterization, up to now 
no analytical techniques have been established for separation and particle size distribution 
analysis of liposomes, especially when the broad size range of liposomes has to be 
covered and characterization in the dispersing medium is required. These aspects are 
discussed in the next sections. 
3.3.1 – Microscopy techniques 
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) are 
often used, since they allow for a direct observation of vesicles. However, sample 
preparation is labour intensive, negative staining and high vacuum analysis conditions are 
required. Moreover, drying procedures may induce conformational changes of vesicles, 
thus limiting the applicability of these techniques to liposome observation in their native 
state [22]. Environmentally Scanning Electron Microscopy (ESEM), is also used because 
of the possibility to observe wet systems without conductive coating, but detailed 
information about surface and architecture of vesicles, observable with TEM or SEM, are 
lost [23].   Cryo-TEM allows for a direct observation of colloids in the vitrified frozen 
hydrate state, thus very close to the native state of samples. Information about size, 
shape, lamellarity, tridimensional structure of single lipid vesicles are accessible. Sample 
preparation is relatively fast compared to other microscopy techniques, however it is quite 
critical for fragile particles like liposomes, because of the possibility to generate and 
observe artefacts due to the freezing and drying processes that induce morphological 
changes or rearrangements of the particle structure. Cryo-TEM is therefore an useful tool 
to investigate specific structural aspects of particles [24] rather than PSD. 
Altogether, this holds true for microscopy techniques (with the exception of ESEM): they 
are not able to analyse vesicles in the dispersing medium and do not provide PSD 
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measurements unless a relevant number of observation are performed to have statistical 
significant data. 
3.3.2 – Atomic force microscopy 
Atomic Force Microscopy (AFM) is one of a number of scanning probe microscopy 
techniques that image a sample surface with a sharp tip or probe. Several papers have 
been published on the characterization of liposomes and on the investigation of specific                                 
issues [25] [26]. For the analysis liposomes are immobilized onto a smooth surface and 
then scanned by the AFM tips. On a comprehensive study on the use of AFM for liposome 
characterization [25] it was demonstrated that this technique could be suitable for the 
analysis of liposome size, but some problems were highlighted. Analysis on dispersion is 
possible only immediately after sample deposition because medium evaporation cause 
vesicles rearrangements in less than 10 minutes, liposomes are not stable once deposited 
on the mica surface [23] and, finally, it has been suggested to obtain images in the so 
called non-contact mode, otherwise, with tapping or contact mode deformations of lipid 
layers occur. Nevertheless even with non-contact mode some vesicle deformation or 
rearrangements were observed. 
3.3.3 – Light Scattering techniques 
Dynamic Light Scattering (DLS) is a widespread and well-established technique for PSD 
measurements [27-30]. Sample manipulation is easy and analysis fast, but in batch mode 
a DLS experiments provides relatively low information.  When sample has wide and/or 
multimodal size distribution, PSD evaluation is limited or biased, restricting the DLS-based 
analysis to non-complex samples with narrow distribution. One way to get through this 
problem is to study the angular dependence of scattered light [31]. Such a LS-based 
technique is Multi Angle Light Scattering (MALS). Together with DLS, MALS represents 
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one of the few absolute methods for particle sizing and molar masses determination and it 
is able to work over a wide range without the use of any standard [10].  
3.3.4 – Size-separation techniques 
As already discussed in chapter the optimal use of LS based detection rely on the on-line 
coupling with size-separation techniques. By coupling SEC or FFF to LS detection it is 
possible to reduce sample complexity and to study of a series of ideally monodispersed 
slices of sample [32]. Size exclusion chromatography (SEC) and HPSEC have been 
applied for lipid vesicles separation. They are based on the same principle, i.e. size-
dependent permeation of solubilized molecules or dispersed molecular aggregates 
through the gel. Liposomes elution is mainly related to their size and shape, however a 
series of other variables influence retention behaviour and recovery [33], among which 
flexibility or rigidity of bilayers. Liposomes interactions with the gel matrix are often 
observed, they derive from the chemical nature of the gel, the lipid bilayer composition and 
the encapsulated material (if any). Column pre-saturation has often found to be necessary 
[34, 35] and mechanical interactions or shear forces are likely to induce vesicle 
degradation or severe alteration of the original PSD of samples. 
AF4 is extensively used for liposome characterizaiton [35-41]. Interesting features are the 
lack of a packed stationary phase and absence of chemical interactions or shear 
stress/degradation mechanism are involved: particle alteration is therefore avoided. 
Furthermore and analysis are feasible in a wide series of dispersing medium. However, 
sample carry-over is a possible issue, and membrane pre-saturation is often necessary. 
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Chapter 4 – Characterization of a 
lipidic dispersion for ophthalmic 
use 
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4.1 – Introduction 
Emulsions of nanosized, phospholipid vesicles have shown able to restore the 
microenvironment of damaged ocular surfaces [42]. This chapter is focused on several 
aspects of the size characterization of a lipidic vesicle dispersion for ophthalmic use. The 
vesicles are constituted of an aqueous and a lipid phase. Main components of the lipid 
phase are the physiological constituents of the lachrymal fluid (phospholipids and medium-
chain triglycerides). The lipid components have shown able to protect the ocular surface 
by forming a thin hydrophobic barrier that is similar to the lipid layer of the lachrymal film. It 
was demonstrated that exposure of cells to phospholipid vesicles may also result in 
unidirectional movement of cell cholesterol to the vesicles [43].  
Possible uptake of cholesterol on phospholipid vesicles is of therapeutic relevance since 
biochemical studies have focused that the excess of intracellular cholesterol may inhibit 
cell proliferation [44]. The actual uptake level depends on the interaction of the vesicle lipid 
components with cholesterol. The uptake process likely involves aggregation/re-assembly 
of the phospholipid bilayer, which should be evaluated using a non-destructive technique 
for biophysical analysis of self-assembling colloidal structures. 
As already stated PSD is a key feature of liposomes, since it affects a number of 
properties including stability, drug encapsulation and bio-distribution, with influence on 
therapeutic effects when drug-loaded liposomes are used.  
In this work we propose an hyphenation of AF4 and MALS as a mature, efficient, and time 
saving technique for liposomes characterization, and to show its performances for the (a) 
characterization of vesicles in different osmolarity conditions of the carrier liquid in order to 
investigate its effect on PSD, and detection of aggregates when they form even in very low 
amounts; (b) evaluation of cholesterol uptake capability in different carriers in order to 
establish the vesicles reactivity with respect to the osmolarity of the dispersing medium: for 
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this purpose experiments in both pathologic and physiologic osmolarity condition were 
performed; (c) evaluation of cholesterol uptake upon spiking of vesicles with increasing 
cholesterol uptake. 
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4.2 – Materials and Methods 
4.2.1 – Samples 
Lipimix emulsions (Tubilux Pharma, Pomezia, Italy) were available on the market as 
formulations for ophthalmic use. They are constituted of an aqueous phase, and of a lipidic 
phase which components are the physiological constituents of the lachrymal fluid. The 
main components are: phospholipids, medium chain triglycerides, soybean oil, glycerin, α-
tocopherol, and distilled water. Samples were stored at 4°C in the dark, as the 
manufacturer suggests. 
All the samples were diluted 1:20 in carrier solution. Injection volume was set to 10 µL. 
Carrier solution was phosphate buffer (salt purchased from Sigma Aldrich) at pH = 7.4 and 
different osmolarities (9, 19, 38, 75, 150 and 300 mOsm/L). Cholesterol was purchased 
from Biolabo, (as part of a chod-pap test kit). 
4.2.2 – Instrumental setup 
AF4-MALS analysis was performed by using a 1100 Series HPLC system (Agilent 
Technologies, Palo Alto, CA), connected to a control module to control AF4 flow rates and 
operations (Eclipse 3, Wyatt Technology Europe, Dernbach, Germany). Detection was 
performed by a MALS DAWN HELEOS detector (Wyatt Technology Corporation, Santa 
Barbara, CA). Carrier solutions were degassed using an on-line vacuum degasser Agilent, 
1100 series (Agilent Technologies). 
The separation device was a 265 mm long channel (Wyatt Technology Europe), equipped 
with regenerated cellulose membrane (Nadir) with a molecular weight cut-off of 10 kDa. 
The channel spacer was 250 µm tick, with trapezoidal shape (upstream width b0 = 16 mm; 
downstream width bL = 4 mm). 
Figure 4 reports the flow program used for vesicles fractionation. 
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Figure 4: Flow program for the fractionation of liposomes 
 
In details the following steps constitutes the flow program: 1 minute focus flow (2 mL/min) 
was applied to equilibrate the flows. Than 5 minutes injection (at a flow rate of 0.2 mL/min) 
in focus mode were applied in order to allow the sample to reach the channel, and two 
further minutes of focus were used to allow for a complete relaxation. After the focus step 
the elution starts. Detector flow had been set to 1 mL/min, while a constant perpendicular 
hydrodynamic field of 0.2 mL/min, namely the cross flow, was applied.  
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4.3 – Results & Discussion 
4.3.1 – Lipimix in different carrier solutions 
Figure 5 reports the LS fractograms of Lipimix. Samples were prepared by dilution of 
vesicles 1:20 in mediums of different osmolarity (respectively 9 mOsm/L; 19 mOsm/L; 38 
mOsm/L; 75 mOsm/L; 150 mOsm/L; 300 mOsm/L), while fractograms were obtained by 
elution of each sample using as carrier the same medium in which vesicles were diluted. 
Salt composition was kept constant, while salt osmolarity varied. Laser Scattering signals 
were recorded at 18 different angles of the MALS detector, and relative scattering 
intensities at 90 degrees are reported.  
 
 
Figure 5: Full lines: LS traces @ 90° of Lipimixeluted in different osmolarity conditions (9, 19, 38, 75, 150, 
300 mOsm/L); Empty squares: RMS radii (nm). 
 
As already explained in chapter 2.4, it is possible to retrieve the RMS distribution in 
correspondence of the peaks directly from the profile of scattering intensity. RMS radii 
traces are represented as squares in Figure 5 and PSD are reported in Table 2.   
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Osm/L (·10-3) RMS (nm) tr (min) 
9 50 – 350 5.6 
19 50 – 200 5.8 
38 50 – 100 6.1 
75 50 – 80 6.4 
150 50 – 75 5.8 
300 50 – 60 3.3 
Table 2: RMS radius and retention times of Lipimix diluted and run in different carriers 
 
As it can be seen, with decreasing osmolarity there is a change in particle size distribution: 
in 9 mOsm/L carrier the particle radius span from about 50 nm to 350 nm, the range 
becomes narrower with increasing osmolarity so that it is 50 nm to 75 nm for 300 mOsm/L 
carrier solution. It is clear that particle size of the vesicles is influenced from the carrier 
solution, and it increase with decreasing osmolarity. This can be due to potential 
aggregation/reassembling of particles. 
It can be observed that there is a difference in retention time with decreasing nanoparticles 
RMS radius when the osmolarity of the carrier solution decreases from 75 mOsm/L to 9 
mOsm/L. This is not consistent with retention theory since elution time is proportional to   
D-1 (the diffusion coefficient) and D is proportional to r-1 (with r hydrodynamic particle 
radius), that is, the smaller the hydrodynamic radius of the particle the earlier it elutes. By 
comparing the ionic strength of each eluted sample, it can be noticed that the higher the 
ionic strength the higher the retention time. It is known and fully accepted that ionic 
strength plays an important role in FFF, and it is of particular relevance when one consider 
the migration of charged particles (as phospholipid nanovesicles are) in proximity of the 
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accumulation wall. Particles at low ionic strength elutes relatively far away from the 
accumulation wall compared to those eluted on higher ionic strength. In the first case a 
decrease of the electric double layer is responsible for the particle to closer approach the 
accumulation wall, while at low ionic strength the opposite occur because of an increased 
electric double layer. For this reasons the velocity of migration is different because 
different is the interaction with the longitudinal, hydrodynamic field. However it is not clear 
why 150 mOsm/L and 300 mOsm/L did not join this trend.   
4.3.2 – Lipimix in different carrier solutions 
A qualitative but smart method for the detection of small quantities of aggregates is the 
observation of LS fractograms recorded at low angles. The MALS detector records the 
scattering intensities at 18 different angles with respect to the laser beam source. It is 
known that the scattering intensity at each angle of detection is proportional to the mass 
concentration of sample and to the RMS radius of the particles. The concentration of 
sample has the same contribution at every angle (there is not angular dependence of 
scattering intensity from concentration). But this holds not true for particle size when the 
scattering is not isotropic. In this case, the higher the RMS radius, the more the photons 
are scattered on the opposite side of the laser beam source, that means, according to the 
scattering theory reference axis, at small angles. As a consequence, observing the 
fractograms at lower and lower angles, the contribution of particle size to the intensity of 
LS signal gradually increases. For this reason it becomes easier to appreciate the 
presence of aggregated/reassembled particles, even when they are present in a very low 
amount. 
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Figure 6: Rayleigh Ratio @ 14.45° for Lipimix in different carriers 
 
In Figure 6 the scattering patterns of Lipimix at 14.45° in different osmolarity are reported: 
in 300 mOsm/L carrier there is a broad and noisy band, and it is even not possible to 
identify any peak, and the same is observed for 150 mOsm/L carrier. In 75 mOsm/L carrier 
the profile is different and constituted by a first band, followed by a second, less intense 
band, at higher retention time. In 19 mOsm/L and 9 mOsm/L carriers, patterns definitely 
show the presence of a second band.  
This observation, together with the already discussed change in RMS radius distribution 
showed in Table 2, suggests a conformational change of vesicles that can be ascribed to 
the change in osmolarity of the mobile phase. 
4.3.3 – Uptake of cholesterol in different osmolarity conditions 
We also investigated the possibility of unidirectional movement of cholesterol from the 
dispersing medium to the lipid bilayer of the Lipimix nanovesicles.  For this aim six 
samples were prepared: two vials of Lipimix diluted 1:20 in 2.7, 300, 316 mOsm/L carrier 
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solution. Injection volume was set to 10 µL. The choice of such carriers was done to 
investigate the uptake of cholesterol in different conditions: 316 mOsm/L is the osmolarity 
associated to the so called dry eye disease; 300 mOsm/L is the normal eye osmolarity, 
while there are not studies reporting hypo-osmolarity conditions of the human eye. To one 
of every couple of vials an aliquot of cholesterol was added, so that the injections 
corresponded to 10 µL of Lipimix 1:20 in carrier solution + 200 ng of cholesterol.  
Three couples of fractograms are reported in Figure 7A, B and C, each one corresponding 
to the injection of Lipimix as it is and to Lipimix after the addition of cholesterol. 
With 2.7 mOsm carrier solution there is clear change in particle size, with radii spanning 
from 56 nm to 314 nm before uptake and 108 nm to 300 nm after uptake. This suggests an 
actual cholesterol uptake. As for 300 mOsm/L carrier solution the dispersion span 45 nm 
to 60 nm before uptake and the particle size increase to 65 – 90 nm after uptake. Finally, 
looking at the 316 mOsm/L fractograms it can be noted that the RMS traces span the 
interval of 50 – 120 nm before uptake and 60 – 150 nm after uptake. 
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Figure 7: LS traces at 90° of lipimix vs lipimix + 200 ng cholesterol, in (A) 300 mOsm/L Carrier; (B) 2.7 
mOsm/L carrier; and (C) 316 mOsm/L carrier 
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4.3.4 – Uptake of increasing amount of cholesterol 300 mOsm carrier  
In the last part of this work we studied the ability of vesicles to interact with increasing 
amount of cholesterol, together with the ability of the technique to detect particle size 
changes even when the added cholesterol is low (compared to the 200 ng reported in the 
previous section). 300 mOsm/L carrier solution was chosen as it is the physiologic 
osmolarity on the ocular surface. Vesicles where diluted 1:20 in carrier and than an aliquot 
of cholesterol was added in the vial, so that for an injection volume of 10 µL the injected 
amount was 10 µL of limpimix 1:20 + 25 ng of cholesterol and 100 ng of cholesterol. 
As it can be seen in Figure 8 with 25 ng of cholesterol particle size increase, the effect is 
more evident with 100 ng of cholesterol. 
 
Figure 8: LS traces of Lipimix with increasing amount of added cholesterol Red: Lipimix + 0 ng of 
cholesterol; Black: Lipimix + 25 ng of cholesterol; Green: Lipimix + 100 ng of cholesterol. 
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4.4 – Conclusions 
AF4-MALS has here shown to be a suitable tool for the rapid assessment of lipid vesicles 
dispersions. (a) AF4 allowed for a rapid size separation, while MALS detection showed to 
be able to detect small quantities of aggregates: by simply observe signals at low angles it 
was straightforward to detect small quantities of aggregates and relate their formation as a 
consequence of the osmolarity of the carrier; (b) it was possible to evaluate the vesicles 
uptake as a function of increasing amount of added cholesterol in physiological conditions 
(thus constant osmolarity of the carrier) and to evaluate the cholesterol uptake of vesicles 
as a function of the dispersing medium by varying its osmolarity. 
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Chapter 5 – Liposomes as 
Elacytarabine vector: an evaluation 
of the interactions with blood 
serum components 
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5.1 – Introduction 
Acute myeloid leukemia (AML) is a genetically heterogeneous group of leukemia, which 
evolves in bone marrow failure, anemia, fatal infection, bleeding, and organ infiltration. The 
standard therapy against AML follows two main objectives: complete remission through an 
induction therapy followed by a post-remission (consolidation) therapy with the aim to 
stabilize the conditions gained during complete remission and prolong it. However the 
majority of patients relapse, giving rise to a more resistant leukemia, which up to now have 
no specifically approved therapy. [45]. 
Nowadays the most common approach is to administer cytarbine, but several mechanism 
of drug resistance inhibits its benefits [46-48]. A strategy to improve its therapeutic effect is 
the administration of elacytarabine[49] which is the fatty acid derivative (elaidic acid ester) 
of cytarbine (Figure 9), synthesized through an esterification reaction between elaidic 
acid(trans-9-octadenoic acid) and the deoxycytidine analogue cytarabine  specifically 
designed to improve antileukemia activity [49]. 
Figure 9: synthesis of elacytarabine: (I) Cytarabine, (II) elaidic acid ester 
 
However elacytarabine is insoluble in water and for parenteral administration it is 
solubilized trough an egg phospholipid liposome formulation [50, 51] a form in which 
liposomes act as drug vector once injected in the blood stream. When lipidic particles are 
injected they come into contact with circulating lipoproteins and cell membranes and they 
have deleterious effects when infused in excess due to the perturbation of several 
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metabolic processes, like exchange and transfer of lipids and apolipoproteins, enzymatic 
hydrolysis of triacylglycerols and phospholipids, and internalization by different tissues. To 
limit as much as possible the metabolic perturbations due to the intravenous administration 
of exogenous phospholipids, the emulsion has to be infused at a low rate, and should 
contain the minimal amount of excess phospholipids [52]. 
Since liposomes is a rather old technology, discovered and first published in the sixties 
[11] several attempts to study their interactions with blood serum component have been 
done [53-55]. The first approach was to set-up simulated and simplified physiological 
conditions so that only the variables and parameters of interest were to be taken into 
account. From a practical point of view, this approach consists on the creation of purpose 
made samples, so that for example, Liu D. et al elucidated the interactions of liposome 
with serum proteins, through a series of experiments using standard or purified serum 
proteins and lipoproteins [56], and the same did Cwiklinska A. et al. [57]. Another 
approach is to administer liposomes to mices for a subsequent blood test, and analysis of 
pre-treated, purified blood samples with technique such as SDS-PAGE separation, 
western blot and ELISA assay [58]. Also nowadays, despite in literature hundreds of 
studies on this subject are reported, it seems that most of them are in-vitro studies 
consisting on the incubation of liposomes with serum component and subsequent analysis 
with various assay [59]. In this context, it is relevant to report that the interactions of 
liposomes with blood serum components is a problem that has not been faced through the 
use of size based separation technique like AF4. 
Since it is of capital importance, this chapter is focused on the study of the fate of the 
elacytarabine drug molecules due to interactions of liposomes once exposed to the 
biological compound of the blood serum. 
The ability of AF4 to size separate blood serum components such as HDL, LDL VLDL and 
chylomicrons has already been reported both for standard and purified samples [60]; the 
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technique has been shown to be effective also to fractionate untreated, whole blood serum 
[61]. 
In this study AF4-MALS is for the first time further developed to identify the blood serum 
species having interaction with the drug carrier, by means of size separation of liposome 
carrying elacytarabine from blood serum components and in particular lipoproteins. 
A first method developed on analytical scale shows that the liposomes retention time band 
is partially overlapped to the serum lipoproteins peak and overloading problems still persist 
after different channel lengths and flow gradients were tested. Instead, a method 
developed on micro-preparative scale improved separation and avoided co-elution of 
liposome with serum lipoproteins, allowing (i) to study liposome / lipoproteins interactions 
(ii) a conformational analysis of liposome, serum lipoproteins, and liposome-lipoprotein 
complexes done by collecting fractions from the AF4-MALS system and analyzing them 
with QELS and (ii) to inject amount of sample high enough for collection for further HPLC 
analysis. 
The study confirmed the presence of interactions between liposomes and lipoproteins 
depending on two main parameters: sample ratio and incubation time. Interactions are 
more evident with increasing time and with increasing liposome to serum ratio; we 
evaluate 1:100 as the lower limit for the detection of liposome in serum. For this ratio 
liposomes are still detectable in the fractogram. The conformational analysis showed a 
change in conformation due to sample interactions, which ends up in aggregation 
phenomena between liposomes and lipoproteins. HPLC–UV analysis revealed two serum 
species to be responsible for the higher drug uptake: IgG and HDL fraction, the former 
having probably high affinity for the apolar lipidic tag of elacytarabine molecules and for 
liposomes lipidic components. The elacytarabine was also found in lipoproteins fractions, 
with high amount. 
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5.2 – Samples and Methods 
5.2.1 – Sample – Analytical scale characterization 
In this work the following samples were used: 
(1) a well-characterized serum sample; 
(2) CP-4055 liposome formulation; 
(3) CP-4055 liposome formulation plus the well-characterized serum sample in various 
ratios, as reported on every section of this paragraph; 
(4) reference samples: Human Serum Albumin (HAS) and an immunoglobulin (IgG). 
A healthy donor whose blood serum has been monitored (in terms of protein and lipidic 
content) for six month right before the starting date of this project provided the serum 
sample. The following parameters were considered relevant for this study: Albumin (69 
kDa), 45 g/L and 21.8 mmHg and globulines (a1, a2, b, g) (140 kDa), 25 g/L. Also the lipidic 
composition in terms of total cholesterol (COLT = 208 mg/dL), triglycerides (TG = 67 
mg/dL), and HDL cholesterol (HDL  = 85 mg/d) was monitored.  The following table reports 
the last blood analysis of the subject. 
Table 3: Concentration of serum proteins of the donor 
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The liposomes were provided by Clavis-Pharma. The formulation is composed of vesicles 
which are mostly unilamellar, with a declared size distribution ranging from 10 nm up to 
200 nm. The surface charge is negative because of the ionized phosphate groups of the 
phospholipids they are composed by. Liposomes were always filtered before use (both for 
injection and previous mixing with serum) using 1.2 µm regenerated cellulose (RC) or poly-
ether sulfone (PES) filters to avoid possible aggregates of vesicles and prevent 
elacytarabine microcrystal to damage the fractionation system.  
Samples containing both CP-4055 liposome formulation and serum sample were prepared 
and injected. From a general point of view, two ratios of elacytarabine mixed with serum 
sample were mostly used, namely 1:20 and 1:200 (liposome/serum, v/v) as they represent 
the typical situation of end and beginning of infusion to the patient, respectively. The 
formulation is in fact administered in the time frame of 24 hours, at the rate of 1,9 g/hour, 
with a consequent time dependent variation on the ratio of liposomes and serum in the 
blood stream.  
The reference samples were albumin from human serum (HSA A3782 Sigma, Human 
Albumin, purity > 99%, free of fatty acids) and a commercial monoclonal antibody (IgG, 
Mw 150 kDa, from a pharmaceutical formulation). 
The following tables summarize the samples used. As for CP-4055 liposomes + serum 
(1:200 - sample I) and CP-4055 liposomes + serum (1:20 - sample II) of table 2 the 
volumes are chosen so that the mass of liposomes is constant despite their ratio with 
serum varies. 
Sample Concentration Injected volume 
Injected 
amount 
 mg/mL µL Μg 
Serum / 4 or 40 / 
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CP-4055 liposomes 10 2 20 
CP-4055 liposomes + 
serum (1:200 - sample I) 
0.5 + Serum* 40 20 
CP-4055 liposomes + 
serum (1: 20 - sample II) 
5 mg/mL + Serum** 4 20 
HSA 10 18 180 
IgG 40 2.5 100 
Table 4: Sample I: Liposomes diluted 1:200 in blood serum (serum to liposome ratio to mimic the 
beginning of the infusion); Sample II: Liposomes diluted 1:20 in blood serum (serum to liposome ratio to 
mimic the end of the infusion) 
 
5.2.2 – Sample – Overloading study 
The purpose of this section was to ascertain if the fractograms were affected by 
overloading and aspecific or method dependent phenomenon, and to determine the 
maximum injectable amount of sample. Two series of injections using the AF4 method 
number 2 reported in Figure 11 were done. The first aimed to verify the overloading effect 
due to total load (Table 5) by injecting increasing amount of a sample with constant 
liposome to serum ratio (Sample I, ratio 1:20).  
Sample Concentration Injected volume Injected amount 
CP-4055 liposomes + 
serum, 1:20 
5 mg/mL+ 
Serum 
4; 2; 0.5  µL 20; 10; 2.5  µg 
Table 5: series of injection with the aim to verify the overloading effect due to total load. Three injection 
with different volumes of sample with the liposome to serum ratio of 1:20 (sample II) were done. Total 
injection amount in µg is also reported. 
 
The second series consists on injections of samples with increasing liposome to serum 
ratio in order to increase the amount of injected liposomes. Three samples with liposome 
to serum ratios equal to 1:20, 1:10 and 1:5 were prepared. By increasing the ratio, the 
injected amount of liposome duplicates (20 µg, 40 µg and 80 µg, respectively) while the 
57 
 
corresponding injected mass of proteins decreases, so that the total amount does not vary 
significantly. 
 
Sample Injected 
volume (µL) 
Liposomes 
mass (µg) 
Serum protein 
mass (µg) 
Total injected 
amount (µg) 
CP-4055 liposomes + 
serum, 1:20 
4 20 228 248 
CP-4055 liposomes + 
serum, 1:10 
4 40 216 258 
CP-4055 liposomes + 
serum, 1:5 
4 80 192 272 
CP-4055 liposomes 2 20 / / 
Table 6: series of injection with the aim to increase the load of liposomes. Liposome to serum ratio are 
1:20, 1:10 and 1:5. Liposome load duplicates, serum protein decreases, so that the variation of total injected 
amount is kept as low as possible.  
 
5.2.3 – Sample – Micro-preparative scale characterization 
Since the analytical scale characterization was affected by overloading issues, an AF4 
method with channel with higher thickness (w= 490 µm) was tested in order to increase 
the injected amount. Samples are reported in Table 7. 
Sample Concentration Injected volume Injected amount 
    Serum  10 µL  
Serum  15 µL  
CP-4055 liposomes 10 mg/mL 10 µL 100 µg 
CP-4055 liposomes + 
serum, 1:20 
5 mg/mL+ 
Serum 
4 µL 20 µg 
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CP-4055 liposomes + 
serum, 1:20 
5 mg/mL+ 
Serum 
10 µL 50 µg 
CP-4055 liposomes + 
serum, 1:20 
5 mg/mL+ 
Serum 
15 µL 75 µg 
Table 7: samples injected for the characterization of samples on the micro-preparative scale 
 
5.2.4 – Sample - Liposome-lipoproteins interactions: incubation time 
and serum to liposome ratio   
In order to study the liposome-lipoproteins interactions, the effect of the following 
parameters were studied: 
(1) incubation times (measurement of liposome + serum blends at t=0, 12 and 24 hours at 
room temperature); 
(2) serum to liposome ratios; 
Samples are reported in Table 8. 
Sample Concentration Injected volume 
(µL) 
Injected amount (µg)  
CP-4055 liposomes + 
serum, 1:20 
5 mg/mL+ 
Serum 
15 75 
CP-4055 liposomes + 
serum, 1:50 
2 mg/mL+ 
Serum 
15 30 
CP-4055 liposomes + 
serum, 1:100 
1 mg/mL+ 
Serum 
15 15 
Table 8: for the micro-preparative characterization three ratios of liposome to serum samples were 
prepared: 1:20, 1:50 and 1:100. 
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5.2.5 – Conformational analysis 
A conformational analysis was performed by evaluation of the RMS/rh ratio, using MALS 
detection for RMS radii and DLS analysis to determine hydrodynamic radii on the collected 
fractions.  
Sample concentration and injected amount are summarized in Table 9. 
Sample Concentration Injected volume Injected amount 
Serum  4 or 40 µL  
CP-4055 liposomes 10 mg/mL 2 µL 20 µg 
CP-4055 liposomes + 
serum, 1:20 
5 mg/mL+ 
Serum 
15 µL 75 mg 
Table 9: sample set of the conformational study 
 
5.2.6 - HPLC-UV drug analysis of collected fractions 
The micro-preparative AF4-MALS method was applied to two different liposomes + serum 
samples in order to collect fractions for the study of elacytarabine drug molecule 
distribution among the blood serum components. 
Seven fractions were collected: HSA, IgG, LDL, lipoprotein band 1, lipoproteins band 2, 
chylomicrons, and field release. The HPLC-UV analysis was performed by means of a 
method optimized for elacytarabine quantification.  
Sample concentration and injected amount are summarized in Table 10. 
Sample Concentration Injected volume Injected amount 
CP-4055 liposomes + 
serum, 1:20 
5 mg/mL+ 
Serum 
15 µL 75 µg 
CP-4055 liposomes + 
serum, 1:100 
1 mg/mL+ 
Serum 
15 µL 15 mg 
Table 10: Samples injected for the fraction collection and drug quantification. 
60 
 
5.3 – Instrumental setup 
The commercial AF4 system was the model Eclipse 3 (Wyatt Technology Europe, 
Dernbach, Germany). HPLC system was a 1100 Series HPLC system (Agilent 
Technologies, Palo Alto, CA). 
Detection was performed by a DAWN HELEOS, MALS detector (Wyatt Technology 
Corporation, Santa Barbara, CA, USA). ASTRA software version 6 (Wyatt Technology 
Corporation) was used to handle signals from the detectors and to compute the RMS 
values. 
The DLS instrument was a Dynapro Nanostar, all the measurements were done in batch 
mode in quartz cuvette, upon fractionation and fraction collection. 
HPLC-UV for elacytarabine quantification was done at Clavis-Pharma, Oslo, Norway. 
5.3.1 - AF4 methods: Analytical scale and micro-preparative scale 
characterization 
A double approach is here presented for sample separation: at first two analytical scale 
method are proposed and strength and drawbacks are discussed, then a micro-
preparative scale method is presented to overcome some issue related to the first. The 
differences between method depends mainly upon the channel volume: for the analytical 
scale method a 152 mm channel with a 250 µm thickness spacer and a 175 mm channel 
with a 350 µm thickness spacer were used, while for the micro-preparative scale method a 
significant increase on channel volume is obtained though the choice of a 175 mm channel 
whit a 490 µm spacer. 
All the measurements were dome using 0.85 g/L sodium nitrate solution (10 mM ionic 
strength), to ensure a sufficient ionic strength generally required for liposome fractionation 
[37]. The carrier solution contains also 22 g/L of glycerol with the purpose to balance the 
osmotic pressure of the carrier with respect to that of liposome core, and prevent osmotic 
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stress of the liposomes [39] and 200 mg/L sodium azide to prevent bacterial growth 
without significantly alteration of the ionic strength. 
Two methods were tested for the characterization of serum, liposomes and serum with 
liposomes. Flow conditions are reported in Figure 10 and Figure 11. 
 
Figure 10: AF4 method 1, used for analytical scale characterization 
 
In method 1 detector flow and focus flow are both 1 mL/min. An elution and a focus step of 
one minute each at the beginning of the method serve to equilibrate the flows inside the 
channel. Then samples is introduced into the channel with an injection flow of 0,2 mL/min 
and focused for 3 minutes.  For the elution, an initial cross‐flow rate of 0,8 mL/min was set, 
and then linearly decreased to 0.10 mL/min in 15 minutes. The crossflow rate was then 
kept constant for 5 min, and finally set to 0.0 mL/min for 5 min. The channel was 152 mm 
long, 16 mm wide, and 250 µm thick. Regenerated cellulose membranes with a 10 kDa 
cutoff were used. 
In order to improve separation in the region between IgG and serum lipoproteins (where 
the peak maximum of liposomes lays) method 2 was set up (Figure 11).  
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Figure 11: Method 2, used for analytical scale characterization (spacer thickness 350 µm) and for 
micropreparative scale characterization (spacer thickness 490 µm thickness). 
 
The initial steps (until sample focusing) are the same of method 1. Focus flow and detector 
flow were again 1 mL/min while initial cross flow was set to 1 mL/min ant kept constant for 
15 minutes. After the isocratic step the cross flow linearly decreases to 0,10 mL/min and 
then a second isocratic step of 0,10 mL/min crossflow lasts for 30 minutes for the complete 
elution of sample. 5 minutes of elution and 5 minutes of elution with an inject flow of 0,2 
mL/min and no cross flow are introduced to wash channel and inject tubings. This flow 
program was used with a 350 µm thickness spacer for the analytical scale method, and 
with a 490 µm thickness spacer for the micro-preparative scale characterization and for 
sample collection for further analysis on DLS and HPLC-UV. The channel was 175 mm 
long, 16 mm wide, regenerated cellulose membranes with a 10 kDa cut‐off were used.  
Isocratic step before gradient
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5.4 – Results & Discussion 
5.4.1 – Analytical scale characterization 
The first purpose of this section is to characterize on an analytical scale a CP-4055 sample 
and a mixture of CP-4055 with serum (sample I and sample II, see sample section, Table 
4). The aim is to identify the bands for liposomes and lipoprotein subpopulations in the 
fractograms and to evaluate the degree of separation between liposomes and lipoprotein 
subpopulations. 
The laser scattering profiles of liposomes fractionated with the analytical scale method 
reported in are shown in Figure 12. 
 
 
Figure 12: AF4-UV/Vis-MALS of CP-4055 liposome samples; two repeated runs with PES and RC filters 
used for sample preparation. 
 
The fractogram is constituted by a quite symmetrical peak at circa 13 min, and a low signal 
due to the field release at 25 min. From the MALS detector the RMS radius distributions 
are calculated; particle size ranges from 10 nm up to 100 nm, with a monomodal 
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distribution, and no liposome aggregates are observed in correspondence of the tail of the 
peak (no particles with radius higher than 100 nm), or in correspondence of the field 
release at 25 minutes. The material of the filters (PES or RC)  used for sample preparation 
does not seem to have a significant effect on sample size distribution. Since a slightly 
lower sample recovery is obtained using RC filters, all the results described in the next 
sections were obtained using PES filters. 
In a first attempt to identify the elution bands of the protein subpopulations which constitute 
a serum samples, the method 1 used for liposomes was also applied for the fractionation 
of serum sample and for the reference samples (HAS and IgG); the laser scattering traces 
are reported in Figure 13 where blue, red and green lines are the results of serum, HAS 
and IgG fractionation, respectively. 
 
Figure 13: AF4-UV/Vis-MALS of serum, HSA and IgG. 
 
Three main bands, §1 at 7 min, §2 at 11,5 min and §3 at 15 min respectively, characterize 
the serum sample fractogram (blue trace). They were identified from the comparison of the 
retention times of the reference samples, which were 7 min for HAS and 12 min for IgG. 
chromatog rams
130110_016_IGG-C168J_100UG
130110_014_HSA_180UG.D
130108_012_SIERO_END_4UL
time	  (min)
0.0 10.0 20.0 30.0
R
el
at
iv
e	  
Sc
al
e
0.0
0.5
1.0
LS
§1
§2
§3
R
el
at
iv
e	  
Sc
al
e
65 
 
Based on these results and on previous AF4 data of serum samples with different methods 
reported in literature [61], we could assign in the serum profile peak §1 to HAS and peak 
§2 to serum immunoglobulins. However a slight difference in retention time between 
human serum IgG (11 min) and reference IgG (12 min) is observed, with the latter eluting 
later: a reasonable explanation of this phenomenon may be due to the reference IgG 
which is a pharmaceutical immunoglobulin coming from a different species. At last, in 
serum fractogram the §3 band eluting in the time range 12-20 minutes may be generically 
assigned to the serum lipoproteins. 
In order to investigate possible interactions of liposomes with blood serum lipoproteins 
during elacytarabine infusion time, sample I and II were injected and the fractograms 
compared to that of serum and liposomes alone. 
Figure 14 shows the fractographic profile of the serum sample, CP-4055 liposome and 
serum sample added with CP-4055 liposome (Sample I, Table 4). 
 
Figure 14: AF4-UV/Vis-MALS of serum, CP-4055 liposome, and serum+CP-4055 (Sample I) 
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Figure 15 shows the fractographic profile of the serum sample, CP-4055 liposome, and 
serum sample added with CP-4055 liposome (Sample II, Table 4). 
Figure 15: AF4-UV/Vis-MALS of serum, CP-4055 liposome, and serum+CP-4055 (Sample II) 
 
Recoveries were roughly calculated: a concentration detector such as RI or PDA detector 
would be required, while the use of MALS detector is usually avoided because signal is 
proportional not only to sample concentration but also to other parameters like sample size 
and molecular weight and to the square of particle surface polarizability (dn/dc). On the 
other hand it was not possible to obtain any reliable signal from the RI detector because it 
is sensitive to the change in pressure inside the channel due to the cross-flow gradients of 
both method 1 and method 2, and at the same time UV-Vis detection was poor because of 
the lack of a convenient detection wavelength for serum and liposomes, since both 
absorption and extinction (scattering) phenomenon take place. For this reasons the use of 
MALS detector has been considered a reasonable approximation, and the evaluation of 
recoveries was done by means of the LS peak areas, following this equations: 
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ATOT = Aserum peak + Aliposome peak 
Recovery % = A sample I or II, peak/ATOT 
 
where ATOT is the total peak area, meaning the sum of Aserum peak, the serum peak area, 
and of Aliposome peak, the area of liposome peak. Values of 98% and 95% of recoveries were 
found for sample I and sample II.  
From the comparison of the fractionation profiles for serum (red traces in Figure 14 and 
Figure 15) and liposomes (green traces in Figure 14 and Figure 15), we can observe that 
in the retention time range for CP-4055 (10-15 min) no species are eluted in serum 
sample. This is evident in Figure 15 for sample II; while in Figure 14 for sample I there is a 
partial overlap with the peak of lipoproteins (§3). Moreover, this peak shows lower 
retention time with respect to sample I, however, also in sample II (Figure 15) the peak 
maximum for liposome corresponds to a minimum in the serum sample profile. In the 
fractionation profiles of the mixtures sample I and sample II (blue trace, in Figure 14 and 
Figure 15), a slight increase in the LS signal is present in retention interval typical for 
liposome. This increase is more evident in sample II where the serum amount in the 
mixture is lower. These results may indicate that liposomes were partially eluted within 
their typical retention interval and partially overlapped to the peak ascribed to serum 
lipoproteins, this hypothesis is confirmed by the almost total recovery obtained for both 
sample I and II. From the overlap of the typical profiles for serum and CP-4055 liposome, it 
is then reasonable to assume that the separation of liposomes from serum proteins is 
feasible. Indeed, it is not possible with the current method to deeper understand the 
behaviour of vesicles in presence of blood serum components. Instead, an increase of 
method selectivity may improve separation between immunoglobulins and lipoprotein 
peaks. Taking into account that no serum components are eluted in the typical retention 
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time interval of liposomes in sample II, an interaction between liposomes and other blood 
serum species could be easily monitored by enrichment of the CP-4055 band. 
An attempt to pursue this objective has been done by fractionating sample on an analytical 
scale with the flow program of method 2 and using a longer channel, and a spacer width of 
350 µm. In Figure 16 the fractographic profiles of liposome, serum and liposomes + serum 
samples are reported (sample prepared and injected according to Table 4). 
 
 
 
 
 
 
 
 
Figure 16: AF4-MALS of liposome, serum, serum + liposome (sample II).  
 
The method contains an isocratic step at the beginning (Figure 11), which has the scope to 
improve the separation in the region between immunoglobulins and lipoproteins, where 
liposomes elutes. However it is evident that liposomes continue to exit with lipoproteins, 
when blends samples are injected (green trace). As a general conclusion it seems that the 
method 2 do not produce improvements on the separation, and a co-elution of liposome 
with serum lipoproteins persists. It is known that high amount of injection is a factor which 
limits separation power in AF4 [36, 62, 63]. Therefore an overloading study was performed 
to discriminate whether possible changes in the band shape of lipoproteins are due to 
actual interaction occurring between lipidic vesicles and serum lipoproteins rather than to 
aspecific phenomenon due to the method itself.  
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A specific approach was followed for this aim (samples were prepared according to Table 
5). First of all (Figure 17a) the liposome to serum ratio of 1:20 was chosen and injection 
with decreasing amount were done (4 µL, 2 µL, and 0,5 µL). In the resulting fractograms, 
the retention times of lipoprotein bands where monitored and compared to that liposomes 
injected with the same method (indicated by the green arrow in the figure). This operation 
provides the injection volume giving no overloading; the resulting fractogram is then 
compared to the serum profile injected with the same volume to evaluate differences 
between serum profile and serum + liposome profiles which might be due to interactions. 
The results are reported in Figure 17b (fractographic profiles of a serum and liposomes + 
serum samples, at the ratio of 1:20, with 0.5 µL as injected volume). In Figure 17c the 
fractographic profiles of samples with liposome to serum ratios of 1:20; 1:10; 1:5 and 
liposomes alone using 4 µL as injected volume are reported.  
By decreasing the total injected amount (Figure 17a) a decrease in retention time for the 
lipoproteins band was observed, retention time shifts from 20 minutes when 4 µL are 
injected to 17 minutes when 2 µL were injected and finally to 16 minutes for the 0,5 µL of 
injected volume; on the same time for the 0,5 µL injection a peak maximum close to the 
retention time typical for liposome appears. This result indicates the presence of 
overloading effects.  When the injected amount is 0.5 µL the resolution is good and it 
allows the distinction of different subpopulation. Moreover, by the comparison of profiles 
for serum and liposomes + serum samples at 0.5 µL as injected volume (Figure 17b) it can 
be noticed that the initial parts of the fractionation (until retention time of liposomes) are 
superimposable. In the retention interval of interest, the lipoproteins band (liposomes-LDL-
VLDL), there is a shift at higher retention times in the serum + liposomes sample. This 
effect can be related to co-elutuion and/or complexation of lipoproteins and liposomes. 
Moreover, the field release is higher with samples with liposomes, this can be explained by 
an iperaggregation phenomena of liposomes. The trend of RMS radius is good, from 10 
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nm (high abundant proteins) to 100 nm (field release) in which aggregates particles and 
chylomicrons species are eluted. In Figure 17c, by the injections of liposomes + serum 
samples with an increased amount of liposomes (black trace), a weak band at retention 
time typical for liposome appears. This effect is less evident with respect to injections at 
different volumes; however, it can confirm potential aspecific interactions between 
liposome and lipoproteins due to overloading effects. Therefore, it can be concluded that  
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Figure 17: (a) AF4-MALS of a liposomes+serum 1:20 sample, injection volume: 4 µL; 2 µL; 0.5 µL; (b) 0.5 
µL of serum + liposome and serum samples; (c) AF4-MALS of samples with liposome to serum ratios: 
1:20; 1:10; 1:5 and liposomes 
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co-elution of liposomes and lipoproteins exists, together with some overloading issues. As 
a consequence the use of a higher spacer, a micro-preparative method with a spacer 
thickness of 490 µm, was considered as further step in the method development. 
The injected volume was increased from 4 µL to 15 µL. In Figure 18 the profiles of 
liposome and liposomes + serum samples at different injection volumes are reported.  
 
Figure 18: AF4-MALS of 4 ul liposomes+serum; 10 ul liposomes+serum; 15 ul liposomes+serum 
 
The three profiles are characterized by the same patterns: a sharp band at the beginning 
of the elution step (minute 10) followed by a weak band ascribed to immunoglobulins (14 
minutes) and a narrow, bimodal and intense band starting at 22 minutes, followed the field 
release band at the end of the method. For completeness the three injection of Figure 18 
were compared to the corresponding injection of blood serum (Figure 19). In this case it is 
evident that the lipoprotein band eluting after minute 22 changes shape after interaction 
with liposomes, and, on the same time, the peak of liposomes alone which is expected to 
lays between immunoglobulins and lipoproteins does not appear in the fractogram. 
Furthermore in Figure 18 the intensity of signals are proportional to the injected amount 
and the retention times are comparable. 
For this reasons it is reasonable to assume that the overloading issues are fixed and that 
at the same time the use of method 2 with a 490 µm spacer (the micro-preparative scale 
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channel) gives interesting insight on the mechanism of interaction of liposomes with blood 
serum components. 
 
Figure 19: (a) AF4-MALS of 15 ul of serum and liposomes+serum; (b) AF4-MALS of 10 ul of serum and 
liposomes+serum; (c) AF4-MALS of 4 ul of serum and liposomes+serum 
 
However it would be considered weak to speculate about liposome to lipoproteins 
interaction only on the basis of the interpretation of fractographic patterns, especially when 
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dealing with complex samples: it reasonable to assume that blood serum samples are 
prone to change with respect to time: phenomenon like aggregation of lipoproteins and/or 
sedimentation of chylomicrons which could act as filter are likely to be involved; obviously 
such phenomenon could affected the results. On the other had, as already explained, 
elacytarabine infusions are administered in the time frame of 24 hours: on the scope to 
give further insights on the behaviour of liposomes, the aging of serum and liposomes + 
serum sample was studied with respect to time. It has been mandatory, given the 
circumstances, to monitor in the same time frame also the serum sample to discriminate 
aging effects by complexation phenomena. Due to the good separation efficiency in the 
lipoproteins region of interest and the increased injected amount suitable also for further 
sample collection and analysis, the volume of 15 µL was chosen as injection volume to 
continue with the study of liposomes interactions.  
5.4.2 - Liposome-lipoproteins interactions: incubation time, 
serum/liposome ratio 
Figure 20 a, b and c show the profiles of liposomes + serum samples at the different ratios 
of 1:20, 1:50 and 1:100, at different incubation times (t=0, 12 h and 24 h; Table 8) while 
Figure 21 a, b and c show the profiles of liposomes + serum samples at the different ratios 
of 1:20, 1:50 and 1:100, at the same incubation time. 
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Figure 20: (a) AF4-MALS of serum; liposomes+serum 1:20 at t=0 (2 runs), t=12 h (2 runs); t=24 h (2 
runs). Typical retention time for liposome; (b) AF4-MALS of serum; liposomes+serum 1:50 at t=0 (2 runs), 
t=12 h (2 runs); t=24 h (2 runs). Typical retention time for liposome; (c) AF4-MALS of serum; 
liposomes+serum 1:100 at t=0 (2 runs), t=12 h (2 runs); t=24 h (2 runs). Typical retention time for liposome 
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Figure 21: (a) AF4-MALS of serum and liposomes+serum (1;20; 1:50; 1:100) samples at t=0; (b) AF4-
MALS of serum and liposomes+serum (1;20; 1:50; 1:100) samples at t=12 h; (c) AF4-MALS of serum and 
liposomes+serum (1;20; 1:50; 1:100) samples at t=24 
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From the comparison among different incubation times for liposomes + serum in Figure 
20a we can notice that at t=0 the profile of liposomes + serum is slight different from those 
of serum sample; a slight increase in the signal at retention time typical for liposome starts 
to appear. Peak shapes at t=12 and t=24 hours are the same, and slightly different with 
respect to t=0, with increased intensity for the lipoproteins band due to the increased 
incubation/interaction with liposomes. In Figure 20 b the peak shape does not vary 
significantly at t=0, 12 and 24 h and a it is observed slight increase in the signal at 
retention time typical for liposome appears. In Figure 20 c (1:100 sample ratio) peak shape 
does not change at t= 0, 12 and 24 and slight increase in the signal at retention time 
typical for liposome appears.  
From the comparison among different liposomes + serum ratio 1:20, 1:50 and 1:100 
(Figure 21 a, b and c) at the same incubation time we can notice that at t=0 (a), a slight 
increase in the retention band intensity at retention time typical for liposomes appears for 
the 1:100 and 1:50 samples and it becomes more pronounced for 1:20 sample. The effect 
of incubation time is evident at t=12h and t=24h (b and c): the increase in liposome band 
intensity becomes significantly more evident for 1:20 sample. 
Moreover, in general, the band eluting after 40 min that is associated to chylomicrons 
present an high variability in intensity and a general lower intensity on lipsoomes + serum 
samples with respect to serum sample alone. However, the serum sample was the first 
sample fractionated, it’s possible that the chylomicrons tend to sediment over time and 
their recovery becomes lower. Moreover, it should be note that the AF4 method is not 
optimized for such a big species. 
As a general conclusion, by comparing the different incubation times for liposomes to 
serum ratio 1:20; 1:50 and 1:100 it is suggested that, depending on the liposomes/serum 
ratio, the differences among t=0 and t=12h and t=24h are more evident. From the 
evaluation of the profiles of different liposome to serum ratios the value of 1:100 is the 
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lower limit for the detection of liposome in serum. For this sample, the liposomes are still 
detectable in the fractogram. In the next section the potential interactions occurring 
between liposomes and lipoproteins are further studied by means of a conformational 
analysis of the species eluting on the lipoproteins band. 
5.4.3 - Conformational analysis 
Conformational studies with SEC or FlFFF and MALS have been done for a variety of 
samples, from proteins to biopolymers to nanoparticles [64-71]. They consists on the 
comparison of rh versus RMS values of samples, and they required the iphenation of a 
separation technique such as FlFFF to a detector able to give information on the size of 
the sample gained through the use of at least one non correlated method. Consequently 
the general approach is to plot the rg values coming from MALS detection versus the 
hydrodynamic radius values coming from the calibration of the FFF method (in which 
retention time is proportional to the diffusion coefficient and hence to the sample 
hydrodynamic size) or from the use of a DLS instrument. 
The approach here taken is to fractionate samples and with the on-line coupling of MALS 
detector compute the RMS values on real time. After fractionation the samples were then 
collected and DLS analysis was performed off-line. 
Figure 22 a, b and c reports the profile of serum, liposomes + serum and liposomes 
samples and the collected fractions are indicated.  
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Figure 22: LS and UV@280 nm signals for serum (a), liposomes+serum (b) and liposomes (c); collected 
fractions for conformational analysis 
 
In Figure 26 the conformation analysis results on serum, liposomes and liposomes+serum 
samples are reported as RMS vs rh. 
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Figure 23: rg vs rh of liposome, serum and liposomes+serum samples. 
 
In Figure 23 the conformational analysis is reported as a plot of rms versus rh. The results 
for serum and liposome + serum sample are also reported as RMS vs retention time and rh 
vs retention time (Figure 24), in order to study the conformation with respect to 
fractionation profile. 
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Figure 24: rg vs retention time (a) and rh vs retention time (b) for serum, liposomes, and 
liposomes+serum samples 
 
We obtained 3 different values of rg/rh for serum, liposomes and liposomes+serum 
samples; indicating different conformations. From the results one can summarize that the 
lipoproteins show an indicative value for rg/rh ~ 0.8 indicative of compact spherical 
particles, while liposomes show a value for rg/rh ~ 1.8.  
The value measured for liposomes + serum samples was ~ 1.6, suggesting an 
aggregation phenomenon between lipoproteins and liposome or a potential disruption of 
liposomes and reassembly. In order to investigate this issue, the conformation analysis 
was studied with respect to retention times. 
The rg at the same retention time is higher for liposomes + serum sample with respect to 
serum and liposomes samples (Figure 24b), while the rh values shifts at higher retention 
times for liposomes + serum samples (Figure 24a).  These results indicate aggregations 
phenomena.  
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5.4.4 - HPLC-UV drug analysis of collected fractions 
The last aim of this work is to determine the serum proteins responsible for uptake of 
elacytarabine drug molecules. Figure 25 is an example of fractionation profile of a 
liposomes + serum 1:20 sample, and time interval of the collected fractions is reported on 
the box (F1 to F7). The same fractions were collected from liposomes + serum 1:20 and 
1:100 samples at t=0 and t=24h, and they were are chosen to monitor all the different 
species that were attributed in the fractogram, that is HAS (F1), IgG (F2), LDL (F3), 
lipoproteins band 1 (F4), lipoproteins band 2 (F5), chylomicrons (F6) and field release 
(F7), as reported in Table 11. The method used is the micro-preparative one (flow 
conditions of Figure 11, detector flow is 1 mL/min and fractions were collected for 2 
minutes and the operation repeated for 2 times, for a total sample volume of 4 mL each 
fraction. 
 
 
 
      
Figure 25: AF4-MALS of liposomes+serum. 1-7 collected fractions (in this example, run 187, liposome to 
serum ratio is 1:20) 
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In Figure 25 a scheme of collected fractions and pooled runs is reported. 
 
 
 
 
 
Table 11: collected fractions; fractionated samples 
 
Figure 26 shows the results of HPLC-UV analysis. Elacytarabine peaks were calculated 
and converted in concentrations (gL/mL) as a function of fraction number. The results 
indicate that the higher amount of drug was found in fraction 2, the IgG fraction. It might be 
that on these fractions the HDL are eluted; so they are responsible for interactions with 
liposomes. LDL gives no interaction with the drug molecules, while the elacytarabine were 
also found in fractions 4 and 5, the lipoproteins fractions, with high amount. 
The developed method is able to give fractions suitable for the HPLC-UV drug analysis, 
with only two pooled injections. Also the limit of detection, was calculated and found to be 
satisfactory for further, systematic studies (LoD < 0.007 µg/mL). 
 
Figure 26: results of HPLC-UV analysis of collected fractions. mg/ml of elacytarabine vs fraction numbers 
for -1:20 liposomes+serum sample at t=0 and t=24 h; and for -1:100 liposomes+serum samples at t=0 and 
t=24 h. 
2 min (2 mL fraction)
F1:  9-11 min (HSA)
F2: 13-15 min (IgG)
F3: 19-21 min (LDL)
F4: 26-28 min (lipoproteins band)
F5: 32-34 min (lipoproteins band)
F6: 37-39 min (chylomicrons?)
F7: 57-59 min (field release)
Fractionated samples:
2 pooled runs for sample 1/20   at t=0 and t=24h
2 pooled runs for sample 1/100 at t=0 and t=24h
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5.5 - Conclusions 
From the results one can summarize that: 
(1) an analytical scale method for the size-based separation of serum component and for 
the size characterization of liposomes  was developed. The goal was the improvement of 
the separation in the retention range between IgG and lipoproteins in a way to ‘create’ 
separative space for the elution of liposomes in between. The objective was not pursued: 
results indicate that liposomes still continue to exit with lipoproteins but it was not possible 
to discriminate whether co-elution is due to sample interactions or to aspecific 
phenomenon due to the method. 
(2) The nature of co-elution of liposomes and lipoproteins was further investigated. An 
overloading study was performed in order to understand if it is an aggregation or an 
aspecific issue due to the method. The results indicate that there is an overloading effect 
due to the injected amount; and aggregation phenomena occurred. 
(3) A micro-prep AF4-MALS method was then developed employing a channel height of 
490 µm in order to avoid overloading and to allow increasing the injected amount. Higher 
sample loads were possible and the separation of lipoprotein - IgG - albumin was 
satisfying; and some differences between serum and liposomes + serum samples can be 
observed in the lipoproteins range. 
(3) The liposomes/lipoproteins interactions were studied. Different incubation times for 
serum/liposome ratio 1:20; 1:50 and 1:100 were compared. Depending on the 
serum/liposome ratio, the differences among t=0 and t=12h and t=24h are more evident. 
Moreover, the comparison of fractionation profiles of different liposome to serum ratios 
confirms the presence of interactions with increased effect over time.  
(4) Conformation analysis studiy on the “lipoproteins elution band”, confirmed aggregation 
of liposomes and lipoproteins. 
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(5) An HLPC-UV analysis of elacytarabine distribution was performed on collected 
fractions with good analytical performances. The results indicate that the higher amount of 
drug was found in the IgG fraction. The hypothesis is that on this fraction the HDL are 
eluted; so they interact with liposomes. Elacytarabine was also found in fractions collected 
from the “lipoproteins” fractions, with high amount. 
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Section 3: FlFFF of functional 
nanoparticles in the context of drug 
delivery applications and nanorisk 
assessment 
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Chapter 6 – Characterization of 
Metal Organic Frameworks, a new 
material for azidothymidine delivery 
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6.1 - Introduction 
One of the most used strategies in HIV therapy is the inhibition of retrotranscription and 
synthesis of proviral DNA. The class of drugs that exerts such a function is the Nucleoside 
Reverse Transcriptase Inihibitors (NRTI). NRTI are drug molecules whose chemical 
structure is the modified version of a natural nucleoside. These compounds suppress 
replication of retroviruses by interfering with the reverse transcriptase enzyme. The 
nucleoside analogues cause premature termination of the proviral (viral precursor) DNA 
chain. This class of drugs includes, among the other, azidothymidine (AZT). 
AZT exerts its activity, like all NRTIs, via the metabolization to the triphosphate derivative 
[72, 73].  Phosphorylation takes place in the host's cells prior to nucleoside analogue 
incorporation into the viral DNA. However the process, which is actuated by the 
intracellular kinases, has very low efficiency [74]. Therefore the strategy to overcome this 
problem is to administer directly the triphosphate derivative of AZT (AZT-TP). Its molecular 
structure is reported in Figure 27. 
 
Figure 27: Azidothymidine triphosphate 
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However AZT-TP has some important problems which hinder its efficacy, like (a) short 
plasma half-life (1 h), (b) dose-dependent toxicities, (c) demands of frequent administration 
of high doses to maintain therapeutic drug levels (d) fluctuations of plasma drug 
concentration in intravenous administration with an initial high concentration that increases 
the risk of haematological toxicities and subsequent low drug levels those are below the 
therapeutic threshold (e) extensive first pass metabolism in oral administration.  To 
overcome this bottleneck alternative strategies of administration are required. 
Metal organic frameworks (MOFs) have gained increasing attention in the recent years 
due to their application in a variety of fields, such as gas storage, gas/vapor separation, 
catalysis, luminescence, as nanostructured materials. [75]. Moreover, in drug delivery they 
are used as carrier able to modulate the drug release of hosted entity like drug molecules, 
gene or proteins, to solubilize poorly soluble drugs and protect drugs from physiological 
degradation, [76]. They have been proposed also as valuable non-toxic nano-carriers for 
many anticancer and antiviral drugs like busulfan, cidofovir, doxorubicin and AZT-TP [77]. 
As nanostructured carriers, MOFs have to meet requirement such as bioavailability, non-
toxicity and stability. Furthermore it has recently been reported that for medical 
applications a certain amount of chemical instability in the material becomes a desirable 
property, since the purpose of the carrier is to deliver and release the drug and once this 
function is completed it can degrade in situ [78]. 
The MOF used in this work is the MIL-100 (Material of Institute Lavoisier), whose structure is reported in  
Figure 28. Several ways of synthesis have been studied for this material, from hydro-
solvothermal synthesis under dynamic or static, ambient or autogenous pressure 
conditions, assisted or not by microwave irradiation. The most interesting results come 
from the microwave assisted hydrothermal synthesis which is up to now the fastest one 
and gives high yields of small (<100 nm) and low polydispersed nanoparticles [79]. 
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Figure 28: MIL-100 structure 
 
MIL-100 is composed by FeIII ions coordinated to a non-toxic, biocompatible carboxylic 
acid (trimesic acid). The resulting structure has coordinatively unsaturated sites (CUS) 
able to interact with host molecules. 
The literature reports that AF4-MALS have been successfully used for the size-analysis, 
study of stability and drug release of NPs of different composition, since it allows for 
accurate size distribution analysis, investigation of NPs aggregation in native conditions, 
separation of the unbound constituents of the functional NPs and determination of the 
optical features of the NPs (separated from other dispersion components including free 
chromophores, or free drugs) [41]. Some example of its use on drug delivery nanoparticles 
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are the characterization of lipidic/liposomes particles [39, 80, 81], organic polymer particles 
like micelles (amphiphilic molecules), polymerosomes, dendrimers, nanocapsules and 
polymeric NPs [82, 83], [84-87]  and biopolymer particles [88-92]. 
Given the importance of size distribution, morphology, size stability and functionality of 
drug vectors, in this work we propose AF4 coupled with MALS detection for the 
characterization of MOFs sample as carrier of NRTI drugs for the first time, with the 
following goals: 
(1) to study the particle size distribution of MOFs; 
(2) to study the particle size stability of MOFs over 24 hours; 
(3) to qualitative evaluate the interaction of MIL-100 with 3 azidothymidine derivatives. For 
this aim four samples were chosen: the nude particles and the particles after interaction 
with drug in 3 different degrees of phosphorilation: azydothymidine (AZT, not 
phosporylated drug), azydothymidine monophosphate (AZT-MP) and azydothymidyne 
triphosphare (AZT-TP). 
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6.2 – Materials and methods 
6.2.1 - Samples  
MIL-100 (Fe) nanoMOFs were received from UMR CNRS 8612, Institute Galien Paris-Sud, 
as EtOH wet material, and stored in the dark at room temperature. Synthesis is achieved 
by means if an hydrothermal  microwave assisted reaction described elsewhere [93]. An 
aliquot of wet material was suspended in a few mL of ethanol, then centrifuged (10 min, 
10000 rpm) and subsequently washed two times with milli-Q water to completely remove 
the ethanol. Four samples were prepared, one was unconjugated MOF and the other three 
were drug conjugated MOFs (azidothymidine, azydothymidine monophosphate and 
azytothymidine triphosphate; MOF-AZT, MOF-AZT-MP, and MOF-AZT-TP, respectively). 
Aliquots of the centrifugate were taken and re-dispersed in water or aqueous solution of 
drug to achieve a final concentration of 0.02 mg/ml of the starting solid MOFs material and 
0.02 mg/ml of MOFs and 0.1 mM of drug for the drug conjugated particles. 3’-azido-3’-
deoxythymidine (AZT, Azido 3'- deoxythymidine, Moravek), 3’-azidothymidine 
monophosphate (AZT-MP, 3'-Azido-3'-deoxyD-thymidine 5'-monophosphate sodium salt, 
Carbosinth), 3’-azidothymidine triphosphate (AZT-TP, 3'-Azido-2',3'-dideoxythymidine-5'-
Triphosphate lithium salt, TriLink) were used as received. Drugs were loaded within MOFs 
simply by impregnation (nanoparticles were incubated with aqueous solution of drug at 
room temperature for some minutes).  
6.3 - Instrumental setup  
6.3.1 – Separation and detection systems 
AF4-MALS analysis was performed by using a 1100 Series HPLC system (Agilent 
Technologies, Palo Alto, CA), connected to a control module to control AF4 flow rates and 
operations (Eclipse 3, Wyatt Technology Europe, Dernbach, Germany). On-line detection 
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of the eluted species was performed with a MALS DAWN HELEOS detector (Wyatt 
Technology Corporation, Santa Barbara, CA). Carrier solutions were degassed using an 
on-line vacuum degasser Agilent, 1100 series (Agilent Technologies). 
The separation device is a flat channel with a trapezoidal shape and capillary height. The 
channel was 152 mm long (Wyatt Technology Europe), equipped with a polyethersulfone 
membrane (Nadir), with a molecular weight cutoff of 10 kDa. The channel spacer was 350 
µm tick, with trapezoidal shape (upstream width b0 = 16 mm; downstream width bL = 4 
mm). 
Figure 29 reports the flow program for the separation. 
 
Figure 29: flow condition for the separation of MOF nanoparticles 
 
It was set up as follows: two minutes of elution (cross-flow 0.2 ml/min) were applied to 
equilibrate the baselines on the detectors, then one minute focus-flow (0.5 mL/min) was 
applied to equilibrate the flows in the channel. Then 2 minutes injection (at a flow rate of 
0.2 mL/min) in focus mode allow the sample to reach the channel, and two further minutes 
of focus were used to allow for a complete relaxation. After the focus step the elution starts 
with an isocratic cross flow step of 0.2 mL/min for 30 minutes. I final step of 10 minutes 
with no cross-flow was added to wash the channel and ensure complete elution of all 
particles. 
6.3.2 – Zeta potential measurements 
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The nanonoparticles zeta potentials were measured with a Malvern® Nano-ZS instrument, 
Zetasizer Nano series, UK. 
6.4 – Results and discussion 
6.4.1 – MOFs particle size distribution 
Figure 30 reports the Light scattering signal of the four samples at t=0. MOF particles were 
reconstituted, drug was added and the sample has been injected immediately after 
preparation.  
 
Figure 30: fractograms of MOF samples immediatey after preparation. MOF-AZTTP; MOF-AZT-MP; 
MOF-AZT; Unconjugated MOF. 
 
All the fractograms are constituted of a first peak at minute 8, corresponding to the 
beginning of the elution step. It is due to both very small particles and to large aggregates 
that are not retained with the flow program of Figure 29. Then the main elution band 
appears, with variable intensity for the four samples. Unconjugated MOF has the weakest 
signals compared to the other samples, and the ratio between the void peak and the 
elution band is approximately 1, indicating that a certain amount of the starting material did 
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not take part in the nano porous MOF structure. Both the Gaussian shape of the peak and 
the monomodal distribution indicate a quite monodisperse sample, the RMS traces confirm 
this observation and the particle size is calculated to be around 80 nm. The same 
observations hold true for the MOF-ATZ-MP sample, furthermore it has about the same 
particle size distribution (85 nm). MOF-AZT-MP has a much more intense signal, with the 
left part of the peak quite Gaussian while the right branch is prolonged toward high 
retention time making the peak asymmetric. Particle size distribution is higher than those 
of unconjugated MOF and MOF-AZT, being about 90 nm. MOF-AZT-TP, has the most 
intense peak, it is also symmetrical, with a particle size higher than all the other samples, 
about 96 nm. RMS radii values are summarized in Table 12. 
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6.4.2 – MOF conjugation with drugs 
From the variations of particle size and particle surface charge some considerations about 
the conjugation of MOF with the various azidothymidine derivatives are possible. 
Conjugation is here evaluated, by the means of MALS detection through the calculation of 
RMS radii and by zeta potential measurements of particles. Particle size distribution gives 
information on possible changes of the mass distribution of the particle itself once the 
interaction with other molecules, in this case drug molecules, occur. Zeta potentials gives 
information on particle charge, which depends upon the species bind to particle surface.  
The RMS radius distributions of the four MOF samples at t=0 and at t=24 hours are listed 
in Table 12. Since all the samples are monodispersed, it make sense to report the 
distributions as a single value.  
Sample rms (nm) 
 1 hour (t=0) 24 hours (t=24) 
MOF 80.79 ± 2.16 85.59 ± 2.22 
MOF-AZT 80.78 ± 2.19 80.37 ± 3.11 
MOF-AZT-MP 90.19 ± 2.03 89.75 ± 2.22 
MOF-AZT-TP 96.78 ± 2.38 96.37 ± 2.21 
Table 12: rms radius values expressed in nm of samples immediately after preparation and after 24 
hours. 
 
Zeta potential measurements are reported in Figure 31. 
In Figure 30 and Table 12, it can be noticed that unconjugated MOF and MOF-AZT have 
exactly the same size (about 80 nm). therefore very poor interaction between 
azidothymidine and MOF can be hypothesized. When AZT-MP and AZT-TP are added to 
the particles, the distribution promptly increases to 90 nm and 96 nm. For this reason, it is 
possible to assume that the conjugation occurs. That fact that particles were reconstituted 
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and the AZT-MP solution immediately added indicates also a fast kinetic of conjugation: 
complexation of nanoparticles takes place in the minutes scale. 
A hypothesis about the mechanism of complexation might be that the phosphate groups of 
AZT-MP and AZT-TP are involved on the conjugation and play a key role on the binding. 
 
Figure 31: zeta potential of MOF, MOF-AZT, MOF-AZT-MP, and MOF-AZT-TP. 
 
In Figure 31 all the particles have fluctuating surface charge, but on the average MOF-
AZT-MP and MOF-AZT-TP have a negative charge which absolute value is higher when 
compared to MOF-AZT and most of all to MOF. These trends confirm that AZT-TP and 
AZT-MP actually bind MOF particles, while AZT gives poor interaction. Also the role of 
phosphate groups is confirmed to be crucial for the binding. 
Zeta potential has also a key role on the elution behavior of particles because it influences 
relaxation inside the channel and retention time. Despite the theory would suggest smaller 
particles to elute first, in Figure 30 it can be noticed that the retention time is inverted 
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because larger particles elutes first. Since the channel membrane is negatively charged, 
conjugated particles are repelled away the membrane and they travel at higher position 
compared to unconjugated ones, where the flow stream is higher. The result is that bigger 
particles, in this case, elutes before the smaller ones (MOF-AZT-TP and MOF-AZT-MP 
have lower retention time than unconjugated MOF and MOF-AZT).  
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6.4.3 – Stability studies over 24 hours 
In Figure 32 are reported the LS fractograms of unconjugated MOF samples immediately 
after preparation (red fractograms and rms distributions) and after 24 hours (black 
fractograms and rms distributions). 
 
Figure 32: unconjugated MOF samples, at t=0 and after 24 hours, t=24 
 
At t=0, the fractogram is constituted by Gaussian, monomodal distribution band, with a 
maximum at 18 minutes followed by a small shoulder at 22 minutes. After 24 hours (black 
traces), the trend is inverted, since unconjugated MOF samples gives a fractogram 
characterized by a band having two distinct maximum, the lower one at 18 minutes and 
the second, highest one, at 22 minutes. Despite the root mean square distributions are 
superimposable, this change in band shape indicates the start of an aggregation 
phenomenon.  
The same analysis was performed on MOF-AZT samples, and results are reported in 
Figure 33. Immediately after preparation the fractogram is constituted by a Gaussian, 
intense and symmetric band. The maximum in the retention time band at t=0 is at 15 
minutes, at this retention time after 24 hours of incubation the fractogram has only a weak 
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band (slightly shifted toward higher retention times, at about 16 minutes) and a second 
main band at 29 minutes.  
 
Figure 33: MOF-AZT sample, injection at t=0 and at t=24 hours. 
 
Also in this case a the RMS traces do not indicates significative changes on the particle 
size distribution, however the fractogram shape suggests some aggregation on the 
sample. 
 
Figure 34: MOF AZT-MP sample, injection immediately after preparation and MOF-AZT-MP at t=24 
hours. 
 
Figure 34 shows the fractograms of the MOF-AZT-MP system. The two bands relative to 
t=0 and t=24 hours both indicate monomodal distributions. The dispersion seems to be 
stable in the 24 hours time frame, since there is only a little variation in the LS signal 
intensity, and the PSD given by the RMS radius does not vary with time. 
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Figure 35: MOF AZT-TP at t=0, MOF AZT-TP at t=24 hours 
 
Figure 35 shows the fractograms of the MOF-AZT-TP system. Elution bands are both quite 
symmetric, and signal intensities are comparable. Also the retention times are equal (12 
minutes), indicating the stability of samples. 
Zeta potential, is known to influence nanoparticle stability. For this reason one can assume 
that the aggregation phenomena suggested by the fractograms of unconjugated MOF and 
MOF-AZT (Figure 32 and Figure 33) are due to the absence of phosphate groups that 
leads to a particle charge that is more fluctuating and with values closer to 0 (Figure 31) 
compared to that of MOF-AZT-MP and MOF-AZT-TP. 
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6.5 - Conclusions  
From a general point of view, the MOF particles here studied show no significative 
changes in RMS radius in the time frame of 24 hours. Phosphate groups contribute to the 
stability of particles giving a strong negative charge to the particle surface, so that the 
stability partially depends from conjugation. As a result, MOF-AZT-TP and MOF-AZT-MP 
are the most stable system, and their fractograms do not change with time. Unconjugated 
MOF and MOF-AZT seem to be stable as well according to the RMS radii, but fractogram 
shapes clearly indicate aggregation phenomena. 
Conjugation with drugs was studied both with zeta potential measurements and through 
RMS distribution analysis. AZT gives poor conjugation, while AZT-MP and AZT-TP are 
uptaken from MOF particles. 
AF4-MALS is here shown once again to be a useful methodology to analyze particles used 
in drug delivery application. The size separation together with the unique gentle separation 
mechanism is crucial to avoid loss of aggregates and to detect them, allowing for the 
identification of aggregates even when they are present in sufficient small amount to do 
not vary significantly the particle size distribution. 
Morphological characterization is straightforward from the evaluation of RMS distributions, 
the same is for particle size stability. A starightforward evaluation of the drug conjugation 
was possible as well. 
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Chapter 7 – Hollow Fiber FlFFF 
coupled to ICP-MS for the rapid 
detection of metal nanoparticles 
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7.1 – Introduction 
 
It is today a subject of increasing relevance for the scientific and industrial community the 
definition of protocols for the quality control and risk assessment of nanoparticles and 
nanodevice - engineered materials in general. 
In the previous chapters are discussed various aspects of the characterization of particles 
for application in medicine, a field that for historical reasons has rigid and defined protocols 
of controls aimed to ensure the quality of the materials in use. However, the number of 
nanoparticle-containing product is immense, and many of them were put on the market 
before the international community started to focus on the theme of nanorisk. In this 
chapter the characterization of nanoparticles is devoted to assess the risk involved onto 
the use of a widely spread material-containing nanoparticles: tattoo inks. This material has 
been chosen for two main reasons, the first of which is that it is widely used, while the 
second one is because tattoo inks are injected on the skin by deposition under the first 
superficial layer of epidermis, where they lay for the rest of the individual’s life without any, 
or at least not known, mechanism of metabolism. Being the time of residence of inks under 
the skin virtually infinite, the hypothesis of either instant or gradual release on the body 
fluids of dangerous or potentially hazardous substances has not to be excluded. 
The characterization of a set of tattoo inks is here proposed with the purpose to perform an 
elemental characterization and then to investigate whether metal NPs are present or not in 
the samples. For the first aim an AF4 and an HF5 methods are developed to size separate 
and characterize the inks, by means of MS compatible carrier solutions. AF4 and HF5 
performances are then briefly discussed. HF5 was then hyphenated with ICP-MS for the 
element identification and to determine the elemental composition of anoparticles 
contained in the inks.  
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7.2 – Materials and methods 
7.2.1 - Samples  
All original samples (red, white, brown, orange and black inks) were used as received from 
manufacturer without any chemical pre-treatment. Inks were diluted 1:2000 in 0.1% Triton 
X-100. The diluted samples were sonicated for 15 min prior to injection. The sample 
dilution in surfactant and the sonication had the purpose of disrupting large particles 
aggregates, which could interfere with the separation process and/or be out of the FFF 
operational range or even lead to aggregates formation (NPs coating the surface of 
existing aggregates). 
Triton X-100 surfactant was purchased from Fluka.  
7.2.2 - Methods  
For the HF5 separation, the injection volume was 2µL. Milli-Q water  was used as mobile 
phase, both for simplicity (compatibility with water-soluble tattoo inks) and because pure 
water is more suitable than buffers which contain salts for the coupling with ICP-MS. The 
HF5 employed separation methods and flow conditions ere described in Figure 36. 
 
Figure 36: flow conditions for HF5 separation. 
 
Focus Flow was 0.85 mL/min and detector flow was 0.5 mL/min. The method starts with 
one minute of focus, followd by 3 minutes of sample injection and focusing. Afterwards ten 
minutes of elution with a cross flow gradient linearly decreasing from 0.30 to 0.10 mL/min 
and 10 minutes of isocratic cross flow of 0.10 mL/min allow for sample separation. At the 
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end of the method 2 minutes of elution and injection with no cross flow were put to wash 
the system. The channel was 17 cm long cylindrical PES membrane with a 0.8 mm 
internal diameter and a 10 kDa cut-off. Both UV signals (at 280 nm) and LS signals were 
recorded. 
In Figure 37, the flow conditions for the AF4 method are reported. 
 
Figure 37: Flow conditions for AF4 separation 
 
Also in this case injection volume was 2 µL. The channel was 265 mm long equipped with 
a regenerated cellulose ultrafiltration membrane (cut-off 10 kDa) and a spacer 250 µm tick 
with trapezoidal shape. Detector flow and focus flow were 1 mL/min each, inject flow was 
0.2 mL/min. Elution and focus steps at the beginning of the method were put to equilibrate 
the flows in the separation system. Afterward sample was injected and focused for 3 
minutes. For the separation of NPs a cross flow gradient from 1.00 mL/min to 0.1 mL/min 
followed by 5 min of 0.1 mL/min cross-flow was used. 
7.3 - Instrumental setup  
Separation systems were an Eclipse 3+ for AF4 separation (Wyatt Technology Europe) 
and an Eclipse DUALTEC (Wyatt Technology Europe) for HF5 separation, equipped with a 
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1100 and a 1200 Agilent HPLC systems, respectively. Detection was operated by a MALS 
detector (model Dawn Heleos, Wyatt Technology Europe). 
ICP instrument was an iCAP Qc ICP-MS (Thermo Scientific), on-line coupled with a 
Dualtech (Wyatt Technology) separation system. After separation sample was indrotucted 
on the ICP by means of a PFA-ST nebulizer, equipped with a Quartz glass spraychamber 
(Quartz 2.0 mm ID injector, Ni sample cone, Ni skimmer cone). The quadrupole cell was a 
Qcell, operating in KED mode. He flux was 4.8 mL/min. 
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7.4 – Results and discussion 
 
The HF5 method was applied to the fractionation of black ink sample in order to obtain 
characteristic size-based fractionation profiles, results are reported in Figure 38. 
 
 
Figure 38: UV signal at 280 nm (green line) and light scattering signal at 90° (red points). 
 
The elution UV profile shows a slightly tailed and broad (over 8 min) gaussian peak 
indicating a monomodal distribution of nanoparticles continuously distributed, the LS signal 
maximum is shifted to higher retention time with respect to UV signal, because LS is more 
sensible to bigger particles. In Figure 39 the AF4-MALS profile and RMS values for Black 
ink sample are reported. The fractionation results in a gaussian and symmetric peak 
eluting in a wide interval range and with a peak maximum at 10 min.  
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Figure 39: Fractogram and RMS distribution of Black sample. 
 
Such a gaussian band indicates a monomodal distribution of a single population of 
nanoparticles continuously distributed in the range 30 nm – 300 nm (as indicated by 
values of RMS distribution). Sample is therefore highly polydispersed. 
HF5 peak is 7 minutes, while AF4 peak is 5 minutes. Being the detector flow 0.5 mL/min 
and 1 mL/min respectivley, it means that HF5 allows to fractionate the particles in a lower 
volume with a lower dilution factor. HF5 can operate at low flow rates, which makes it the 
ideal candidate for coupling off/online with mass spectrometry. Therefore the HF5 
separation techniques was then coupled to ICP-MS for a fast screening of further smples. 
The aim was at first to detect metals and then ascertain which of them constitutes 
nanoparticles. For this aim at first Flow Injection Analysis (FIA) were performed. FIA is 
based on the injection of a liquid sample into a continuous carrier stream ao that the 
sample is transported toward a detector that continuously records the the signal due to the 
passage of the sample meaterial through the flow cell [94]. 
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In the case of HF5 a flow injection analysis indicates that no sample components cross the 
permeable, accumulation wall of the HF5 channel and all the species are detected. This 
approach was used for the total elemental quantification. Result are reported in Figure 40.  
 
Figure 40: Relative amount of Cr, Cu, Sn, Fe, Al, Ti, Zn in White, Brown, Red and Orang tattoo inks 
obtained by means of FIA 
 
The graph of Figure 40 reports the relative amount of elements on every ink. White Ink 
contains mainly Ti, brown ink contains high amount of Cu, while Red ink contains high 
amount of Fe. 
Brown, red and white inks were injected a second time with the method of Figure 36 in 
order to determine which elements are assembled on nanoparticles. Results are reported 
in Figure 41a (Cu detection in Brown inks), Figure 41b (Fe detection in Brown inks), Figure 
41c (Fe detection in Red inks), Figure 41d (Ti detection in white inks). 
In Figure 41(a) and (b) retained peaks with maximum at approximately 330 seconds and 
after 1000 seconds indicates that nanoparticles are eluting and that the ICP-MS response 
indicates that they are mainly composed of Cu and Fe. Figure 41(c) indicates that red ink 
contains Fe nanoparticles while white ink contains big and highly retained Ti particles 
according to Figure 41(d). 
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Figure 41: (a) Cu detection in Brown ink, (b) Fe detection in Brown ink, (c) Fe detection in red ink, (d) Ti 
detection in white ink. 
 
7.5 - Conclusions 
In this study it is highlighted that in HF5 the longitudinal flow rate (also known as detector 
flow rate) was 0.5 mL/min. This is the maximum flow rate value – under the specifications 
of the manufacturer. Based on the sample characteristics and on the separation 
performance objectives (resolution, efficiency ecc.), a detector flow rate lower than 0.5 
mL/min is usually employed. Furthermore the HF5 cartridge is commercially available in a 
disposable format  - the separation device can be easily replaced between subsequent 
injections, thus eliminating the sample carry-over effect. Considering the fact that the same 
sample amount was injected (2 µL) and the fact the peak volume is lower for HF5, it is 
proved that HF5 provides better sensitivity when compared to AF4. HF5 operates at lower 
flow rates (which also makes it ideal for the trace analysis and for the on-line coupling with 
ICP-MS, making possible the online analysis of samples to correlate samples properties to 
different size subpopulations). The HF5 separation device has a channel volume of 85 µL 
while the flat channel has channel volume of 465 µL (in the configuration used in this 
study). The volume of flat channel is five-fold the HF5 channel volume, this means that the 
latter provides much lower sample dilution and therefore the UV and LS signals are more 
intense. 
According to these premises the HF5 was suitably coupled to ICP-MS for the fast analysis 
of sample of ink for tattoo. Rather than an in dept characterization of sample which is 
indeed possible, it is here shown that HF5-ICP-MS can be used also as a tool for fast 
metal nanoparticle screening. It is of particular relevance the possibility to work both in FIA 
mode, a procedure that allows for a rapid metal identification and subsequentely 
fractionate the sample in order to identify which species actually form nanoparticles. 
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